

**ENVIRONMENT DIRECTORATE
JOINT MEETING OF THE CHEMICALS COMMITTEE AND
THE WORKING PARTY ON CHEMICALS, PESTICIDES AND BIOTECHNOLOGY**

Cancels & replaces the same document of 28 January 2009

Working Group on the Harmonisation of Regulatory Oversight in Biotechnology

**DRAFT GUIDANCE DOCUMENT ON ASSESSING THE POTENTIAL ADVERSE HEALTH
EFFECTS OF MICRO-ORGANISMS: BACTERIA**

JT03258876

Document complet disponible sur OLIS dans son format d'origine
Complete document available on OLIS in its original format

The first draft of this Guidance Document was presented at the 19th meeting and the revised draft was provided at the 20th meeting by reflecting the discussion at the Moscow Workshop of the sub-working group on micro-organisms held in June 2007.

At the 20th meeting, the Working Group was invited to provide comments on the overall framework and information missing from the version during the next round of comments. It was also agreed that the revised text would be provided by the 22nd meeting of the Working Group.

At the 21st meeting, it was mentioned that the lead countries, the Netherlands and Canada, prepare a new draft for the 22nd meeting and hope to receive major comments. After some discussion, it was agreed that the United States would be invited to send comments on this document to the Netherlands.

This document was redrafted for the 22nd meeting, taking into account the comments from the United States.

ACTION REQUIRED: The Working Group is invited to review this document and provide input as appropriate.

TABLE OF CONTENTS

SECTION I: GENERAL CONSIDERATIONS	4
I.1 The Concept of Pathogenicity	5
I.2 Risk Groups of Bacteria	5
I.3 Approaches to Bacterial Virulence	7
I.4 Outline of the Document	8
SECTION II: BACTERIAL FACTORS AND DETERMINANTS	9
II.1 Host Recognition/Adherence	9
II.2 Host Invasion	16
II.3 Evasion of Host Immune Response & Multiplication in Host	18
1) Adapting to withstand the antimicrobial activity	20
2) Alteration of phagocytosis	21
3) Escape	21
4) Blocking fusion or attenuating acidification	22
5) Phagocytic circumvention	22
6) Multiplication in Host	23
II.4 Ability to Damage or Kill Host	23
SECTION III: MOLECULAR ASPECTS OF PATHOGENICITY	26
III.1 Molecular Genetic Definition of Bacterial Virulence	26
1) Molecular approaches to identify virulence genes	27
2) Trends in virulence gene identification	28
3) The perspective of virulence genes correc	29
4) Classification of virulence genes	30
III.2 Evolution and Spread of Virulence Genes; Pathogenicity Islands	30
SECTION IV: ASSESSING POTENTIAL BACTERIA-MEDIATED ADVERSE HUMAN HEALTH EFFECTS	32
IV.1 Risk assessment of environmental release of bacterial strains that may cause adverse human health effects	32
IV.2 General considerations for assessing changed pathogenicity of parental micro-organisms as a result of genetic modification	34
SECTION V: REFERENCES	36

Tables

Table 1.	Some examples of specific bacterial adherence to host cell surfaces	10
Table 2.	Extracellular bacterial proteins that act as invasins	19
Table 3.	Bacterial proteins that act as immunomodulator	21

SECTION I: GENERAL CONSIDERATIONS

1. This document aims to give guidance on the concept of pathogenicity in the context of risk assessment of deliberate release of micro-organisms. It is limited in scope to bacterial pathogens associated with adverse human health effects. It explores the factors in bacteria which are important for causing adverse health effects and assesses how this knowledge can be used in risk assessment. Where appropriate, the document also refers to certain aspects of animal bacterial pathogens. To cover specific aspects of plant and/or other animal (*e.g.*, fish, insects, and other invertebrates) pathogens, separate documents on these issues will be warranted.

2. Bacteria may cause a hazard for human health and the environment, if they are applied for environmental purposes, *e.g.*, for agronomic applications or in medicinal or veterinary use, including field trials. The analysis from the 'Blue Book' (OECD, 1986) appears to be still valid: 'agricultural applications may result in release of large quantities of modified [micro]-organisms into terrestrial or aquatic ecosystems. Recombinant DNA-derived vaccines for animals and humans, as well as certain plant-associated micro-organisms, will have a much more limited pattern of environmental exposure because of biological specificity to the host, but incidental release to the environment certainly occurs in sewage and feed-lot or run-off waters, and may be significant. Environmental applications (*e.g.*, metal extraction, pollutant and toxic waste degradation) may be confined initially to a specific location or may result in broad ecosystem exposure. The scientific considerations for assessing safety will vary with each particular application, depending on the organism, the physical and biological proximity to man and/or other significant biota. Local quarantine regulations and monitoring methodologies utilized during research and development will also be relevant.'

3. In general, prior to their release bacterial strains should be submitted to an assessment of their potential health effects, *i.e.* their pathogenicity. As 'virulence' is the quantitative measure of the pathogenicity of a micro-organism, the virulence factors of a bacterial strain are its traits that will be taken into account in the risk assessment. For the special case of genetically modified organisms this risk assessment should take into account the characteristics of the modified organism related to pathogenicity, and any introduced traits identified as being associated with pathogenicity.

4. This means that the safety assessment for human health can only be done on a case-by-case basis, taking into account the (potential) health hazards of the bacterial strain depending on the route of exposure (*e.g.*, ingestion, inhalation, dermal contact), and the actual way that exposure to the strain is expected to occur under the conditions of the release. Exposure can depend on a number of factors, including the pattern of release (*e.g.*, aerial spray, ground application, deep well injection, application into water bodies, shedding from inoculated humans or animals) and scale of use (*e.g.*, pilot, field trial, commercial use)

5. Because this document is intended as a general risk assessment tool, its nature is generic, *i.e.* not organism specific, and refers to specific bacteria and characteristics only to illustrate specific concepts. In addition to describing potential adverse health effects, and the bacterial factors that can contribute to these effects, the document describes general considerations in assessing the hazardous potential of non-modified bacteria, including a description of some tools available for predicting adverse health effects. Lastly, the document addresses considerations for the potential to introduce or increase adverse health effects as a result of genetic modifications to the micro-organism.

I.1 The Concept of Pathogenicity

6. Pathogenic bacteria have the ability to invade their hosts and produce infectious disease. In this document, 'pathogenicity' is referred to as the property of a micro-organism to cause infectious disease. The great majority of bacteria that are encountered in the environment are harmless, in the sense that no record exists of them behaving as a pathogen. Some bacteria are even beneficial, *e.g.*, because of their role in essential processes in the environment such as mineralization. Frank pathogenicity in bacteria is the exception. However, there are many bacteria that may act as opportunistic pathogens, organisms that are normally present in the environment or as part of the apathogenic or beneficial flora of a host, but which causes disease when defense systems of the host become debilitated. In general, it is difficult to prove that a bacterium is apathogenic, and probably 'apathogenic' bacteria can best be seen as bacteria that have not yet proven to have pathogenic potential.

7. Although 'pathogenicity' can be defined in terms of properties of a micro-organism, it is important to keep in mind that the concept of pathogenicity is highly anthropomorphic, as it implies that a micro-organism would cause disease 'on purpose'. A more realistic view is that the body is a niche for micro-organisms to adapt to and use as a favourable environment for survival and growth. Bacteria have developed a 'lifestyle' that enables them to colonise this niche in symbiotic as well as in pathogenic ways (Wassenaar and Gastra, 2001). Each body surface – skin, conjunctiva, mucous membranes of the upper and lower respiratory tract, intestinal tract, genital tract, and so forth – harbours a characteristic symbiotic bacterial flora which differs qualitatively from the flora of other areas of the body. The pathogenic lifestyle enables a micro-organism to establish a foothold in this symbiotic system. Once established the lifestyle allows the pathogen to penetrate into deeper tissues, to avoid host defense mechanisms, and to multiply. As they pursue this lifestyle, pathogenic bacteria produce damage to the host. Virulence-associated factors may be defined as all factors that are essential for this lifestyle.

8. Whether a host will develop full blown disease is however not just dependent on the pathogenic potential of the bacterium, but also on host factors. There are a formidable array of specific and non-specific host factors that affect the outcome of an encounter between an animal and a pathogenic bacterium. For example, as noted above the normal commensal flora play an important role in protecting the host from invasion by pathogenic organisms. They do this by mechanisms such as (1) competition for the same nutrients; (2) competition for the same receptors on the host cells (tropisms); (3) production of bacteriocins or other antimicrobial agents (interference); and (4) stimulation of cross-protective immune factors. The commensal flora of the host may be affected by any number of activities (*e.g.*, use of antibiotics). Additional host factors that can affect pathogenicity include the production of antimicrobial substances, *e.g.*, lysozyme in bronchial secretions, or the pancreatic enzymes, bile, or intestinal secretions, or secretion of acid (HCl) for low pH of the stomach. Also, humans have an innate immune system that protects against invasion. When this system breaks down, *e.g.*, in advanced stages of AIDS (Gradon *et al.*, 1992), bacteria that are normally not able to cause disease in humans may become opportunistic pathogens that cause conditions that clinically mimic the more commonly encountered 'frank' pathogens. The potential of bacteria that normally occur in the environment to cause opportunistic infections in hosts with debilitated defense systems is recognized as an important environmental hazard. The case of the *Burkholderia cepacia* complex (Bcc) is an example (Mahenthiralingham *et al.*, 2005). Bacteria of the Bcc are found throughout the environment, some as plant pathogens. It is now recognized that they are also important opportunistic pathogens that can cause variable lung infections and systemic disease in cystic fibrosis patients.

I.2 Risk Groups of Bacteria

9. Pathogenic bacteria are commonly classified in risk groups, according to their pathogenic potential. The classification of the World Health Organization (WHO), as found in their Laboratory safety

manual (WHO, 1994), is generally accepted. It should be noted, though, that these risk groups are primarily concerned with laboratory applications, where exposure may be high. According to this classification, risk group 1 ('no or low individual or community risk') comprises micro-organisms that are unlikely to cause human or animal disease. Risk group 2 ('moderate individual risk, low community risk') comprises pathogens that can cause human or animal disease but that are unlikely to be a serious hazard to laboratory workers, the community, livestock or the environment; laboratory exposures may cause serious infection, but effective treatment and preventive measures are available and the risk of spread of infection is limited. Risk group 3 ('high individual risk, low community risk') comprises pathogens that usually cause serious human or animal disease but do not ordinarily spread from one infected individual to another; effective treatment and preventive measures are available. Risk group 4 ('high individual and community risk') comprises pathogens that usually cause serious human or animal disease and that can be readily transmitted from one individual to another, directly or indirectly; effective treatment and preventive measures are not usually available.

10. For practical reasons, also in regulatory practice, a distinction is drawn between bacteria that are pathogenic to humans and bacteria pathogenic to other animals. Host specificity of bacteria is the result of differences between the environment that bacteria encounter in different hosts, i.e. in the human body and the bodies of other animals. If there are similarities between these environments it may be expected that pathogenic organisms frequently 'jump the species barrier'. Indeed, there are a number of bacteria that are primarily pathogenic to other vertebrates, that are also pathogenic to humans, e.g., *Bacillus anthracis*, *Brucella abortus*, *Yersinia pestis*, *Leptospira* spp. and a number of *Salmonella* species. The human diseases caused by these bacteria are called zoonoses (see also Blancou *et al.*, 2005, for a recent review). In some cases insect vectors play a specific role in passing the pathogenic bacteria from the animal to the human host. Zoonotic diseases are 'animal borne': animals, or animal products, act as a source of the disease. Consequently, exposure to the disease may change with changing social, behavioral and consumer practices. The risk class of a zoonotic bacterial species may differ depending on the host. For environmental risk/safety evaluations of activities with these bacterial species the highest risk class has to be taken into consideration.

11. It is hard, if not impossible, to prove that a bacterial strain is apathogenic. The evidence given for apathogenicity can only be tentative. The decision whether a bacterial strain may be considered apathogenic is usually taken in a stepwise fashion. The strain is considered apathogenic if it belongs to a species for which no pathogenic strains are known. If it has direct relatives that are pathogenic, or if it is derived as an attenuated strain from a pathogenic strain, it should be shown that the strain lacks all virulence determinants of the pathogenic relatives. If this fails, evidence for apathogenicity can be obtained through appropriate animal testing. This requires however a validated animal model. If none of this evidence is available or can be obtained, the strain may be considered apathogenic because it has a long history of safe use under conditions where no specific physical containment has been applied.

12. Although there is clear practical value in using risk groups in practice, e.g., refer to the WHO Laboratory safety manual (WHO, 1994¹, chapters 1 and 2), the concept of 'pathogenic lifestyle' implies that there is a continuum from full non-pathogens to full pathogens. Some bacteria have a lifestyle completely independent of a human or animal host. Others that lack the ability to cause disease may still be able to recognise, adhere to and multiply in or on the host, as commensals. Opportunistic pathogens have some limited ability to cause disease, but are normally kept under control by the host immune response and defense systems. However, they may acquire a foothold, with adverse consequences for the host, generally under circumstances where the host defense mechanisms are compromised (e.g., weakening of the immune system through age or HIV infection) or destroyed (e.g., through skin lesions or burns). Some opportunistic pathogens are acquired from the environment while others may constitute part of the host normal flora.

¹ Available at <http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf>

Some bacterial species causing infections at hospitals are used in bioremediation and/or bioaugmentation processes. For instance, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* are but two organisms used industrially that cause nosocomial infections in cystic fibrosis and burn patients. *Serratia marcescens*, a common soil bacterium, causes pneumonia, urinary tract infections, and bacteremia in compromised hosts. Other bacteria, such as *Lactobacillus acidophilus*, may be considered to be nonpathogens, because they rarely or never cause human disease. However, it should be noted that categorisation as nonpathogens may change, due to the adaptability of bacteria and various detrimental effects (radiation therapy, chemotherapy, and immunotherapy) on host defense systems.

I.3 Approaches to Bacterial Virulence

13. In 1890 Robert Koch established his 'postulates', a standard for the evidence of causation in infectious disease. The evidence should show that (i) the micro-organism occurs in every case of the disease in question and under circumstances which can account for the pathological changes and clinical course of the disease; (ii) after being isolated from the body and grown in pure culture, (iii) the micro-organism can induce the disease anew, and (iv) the micro-organism can be re-isolated after this experimental infection.

14. Virulence factors can be defined in terms of the Koch postulates, as phenotypic properties of a micro-organism that are present in pathogenic strains that fulfill the Koch postulates, but that are not observed in related strains that are not pathogenic. Although the postulates have been generally accepted for over 100 years (Fredricks and Relman, 1996), Koch himself already recognised the limitations of these guidelines. For instance, the ability to cause disease as an invariant virulence trait has been challenged, as in recent years in a more integrated view of microbial pathogenesis it has been recognised that the contributions of both the pathogen and its host are required. The lack of experimental models for human-specific pathogens limited testing of the third postulate, and consequently also the rigorous testing of the role of a virulence factor.

15. Still, based on the notions of Koch postulates a number of virulence factors have been identified because of their clear role in the pathogenicity process or their clear-cut coincidence with pathogenic strains, e.g., adhesins, invasins, haemolysins, or in general cytolysins. With the development of molecular biological techniques, it became possible to identify the genes encoding these known virulence factors, and to identify genes of unknown function of which a possible role in virulence could be determined. This resulted in a new approach of research of microbial pathogenicity, in which the role of specific genes in bacterial virulence was the key point.

16. Virulence of a micro-organism is usually considered the 'degree' of pathogenicity of the micro-organism in a susceptible host. Finlay and Falkow (1997) discuss the various definitions of microbial pathogenicity, and the idea that pathogens can be distinguished from their non-virulent counterparts by the presence of such virulence genes. A virulence factor is a phenotypic trait associated with the virulence level of a micro-organism. The term is also used for a gene product (or group of gene products) that is responsible for the phenotypic trait. Virulence factors add to the pathogenicity, by enhancing one or more of the processes involved in the stages of pathogenicity: (1) the ability of the bacterial pathogen to gain access to the individual by surviving on or penetrating skin and mucous membranes; (2) the in vivo multiplication of the pathogen; (3) the inhibition or avoidance of host protective mechanisms and (4) production of disease or damage to the host. In this document microbial toxins are regarded as virulence factors. Microbial toxins are defined as gene products² produced by a micro-organism that can cause harmful effects in the absence of an active living micro-organism. Still, in most cases the micro-organism

2. Toxins may also be low molecular weight metabolites; this type of toxins is however not taken into consideration in this paper.

producing the toxin has to be established within the host in order to deliver the toxin most effectively. Therefore the phenotypic trait of toxin production may be seen as increasing the pathogenic potential of a micro-organism, while full blown effects of a toxin may be dependent on other virulence factors of the producing micro-organism, *e.g.*, ability to colonize the host. It should however be realized that some micro-organisms that are not regarded as pathogenic also produce toxins.

I.4 Outline of the Document

17. This document provides an overview of the inherent bacterial components attributed to pathogenicity in section II, Bacterial Factors and Determinants. It deals in more detail with the genetics and molecular biology of pathogenicity in Section III, Molecular Aspects of Pathogenicity, Section IV discusses the problems of how to assess the potential adverse health effects of bacteria in an environmental risk assessment of micro-organisms that are deliberately released, including genetically modified bacteria.

SECTION II: BACTERIAL FACTORS AND DETERMINANTS

18. 'Virulence' is a quantitative measure of the pathogenicity of a micro-organism that may be expressed by the ratio of the number of individuals developing clinical illness to the number of individuals exposed to the micro-organism, or in a comparative manner, by the number of individuals that develop clinical illness if the same dose of different micro-organisms is applied to each of them.

19. Pathogenic bacteria have evolved a number of different mechanisms which result in disease in the host. The virulence factors and determinants used by bacteria to interact with the host can be unique to specific pathogens or conserved across several different species or even genera. For instance common mechanisms for adherence, invasion, evasion of host defenses and damage to host cells are shared by profoundly different microbial pathogens. This section examines the inherent bacterial components attributed to pathogenicity.

II.1 Host Recognition/Adherence

20. Bacterial adherence to host surfaces is an essential first step in colonisation, infection and disease production. Colonisation establishes the organism at the portal of entry and organisms usually colonise host tissues that are in contact with the external environment. Whereas intact outer skin is generally impervious to invasion by organisms, surface penetration of the urogenital, digestive and respiratory tracts as well as the mucosal barrier is more easily accomplished. Much of the body that is usually regarded as internal is topologically connected to the exterior. For example, the surfaces of the intestinal lumen, the lung alveoli, the bile canaliculi, and the kidney tubules are continuous with the outside skin. Organisms infecting these regions usually have elaborate adherence mechanisms and some ability to overcome or withstand the constant pressure of the host defenses on the surface. Bacterial adherence to host cells is usually a prerequisite to invasion. Consequently, a great deal of research has focussed on elucidating bacterial mechanisms of adherence to host cells (adhesin biosynthesis, regulation of adhesins, identification of host receptors).

21. Adhesion can be defined as the coupling of a bacterium with a substratum. For the molecules on the surface of the bacterium to interact with molecules on the surface of a host cell or the extracellular matrix (ECM), the two molecules must come into contact, an action that leads to the creation of intermolecular bonds requiring a certain amount of energy or effort to break. Bacterial adherence to a eukaryotic cell or tissue surface requires the participation of two factors: a receptor and an adhesin. The receptors so far defined are usually specific carbohydrate or peptide residues on the eukaryotic cell surface. Many bacterial adhesins are a macromolecular component of the bacterial cell surface which interacts with the host cell receptor. This interaction is usually complementary and specific, although most receptors can bind several ligands. It is this specificity which determines the tropism of the bacteria for a particular tissue.

22. Bacterial adherence to cells or tissue surfaces may be specific or non-specific. Non-specific adherence or "docking" involves attractive forces and allows for the approach and reversible attachment of the bacterium to the eukaryotic surface (Kachlany *et al.*, 2000). Possible interactions and forces involved include: hydrophobic interactions, electrostatic attractions, Brownian movement, recruitment and trapping

by biofilm polymers interacting with the bacterial glycocalyx or capsule (Gilbert and Foley, 1997; An *et al.*, 2000; Ukuku and Fett, 2002; Foong and Dickson, 2004). Specific adherence occurs when the bacterium forms a more permanent, yet still reversible, attachment with the eukaryotic surface and may proceed as one or more steps. Many specific lock-and-key bonds between complementary molecules on each cell surface are formed. Complementary receptor and adhesin molecules must be accessible and arranged in such a way that many bonds form over the area of contact between the two cells. Once the bonds are formed, separation under physiological conditions requires significant energy input. Some Gram positive bacteria with Microbial Surface Components Recognising Adhesive Matrix Molecules (MSCRAMMs) employ a dock, lock and latch mode of ligand binding (Ponnuraj *et al.*, 2003). Generally, reversible attachment precedes irreversible attachment but in some cases specific adherence is not observed.

23. Mammalian cells communicate with each other through cell surface receptors. Once a receptor is bound with its ligand, a cellular response is triggered. Bacterial mimicry of host cell ligands facilitates the initial adherence to, and subsequent invasion of, host cells (Table I). Through host receptor binding, bacteria exploit normal cellular processes to invade cells. When performing a risk assessment, especially in the case of a modified organism, the evaluator should pay particular attention to bacterial ligands and consider the use of the organism or its products. For instance, coagulase negative staphylococci (CoNS) are commonly seen among the normal flora of human skin and mucous membranes as they are ubiquitous commensals of the body including the mouth and throat. Some CoNS, for example, *Staphylococcus epidermidis*, produce lantibiotics (lanthionine-containing bacteriocins effective against other Gram positive bacteria) which have been proposed for use as a food preservative (Ekkelenkamp *et al.*, 2005). Also, Heilmann *et al.* (2003) have described a novel autolysin/adhesin from *S. epidermidis* having both bacteriolytic and adhesive properties. However, *S. epidermidis* has the ability to colonise certain polymer surfaces by the formation of a thick, multilayered biofilm and is responsible for an increasing number of nosocomial infections (Vuong and Otto, 2002). Therefore, various characteristics of one micro-organism should be taken into consideration if one of its components would be used in a new application.

Table 1. Some examples of specific bacterial adherence to host cell surfaces

Bacterium/ Disease	Adherence Factors	Receptors	Attachment Sites	Reference(s)
<i>Bordetella pertussis</i> / whooping cough	fimD; FHA; pertactin; pertussis toxin	VLA5; β 2 integrin via LRI/IAP;	monocytes /macrophages respiratory epithelium	Hazenbos <i>et al.</i> , 1995; Mattoo <i>et al.</i> , 2001; Ishibashi <i>et al.</i> , 2002; McGuirk <i>et al.</i> , 2002
<i>Burkholderia cepacia</i> / opportunistic infection	cable (cbl) type II pili	mucus glycoproteins	respiratory epithelium	Sajjan <i>et al.</i> , 1995
<i>Enterococcus faecium</i> / opportunistic bacterimia	Collagen Adhesine Gene (<i>acm</i>)	collagen	various tissue	Nallpareddy <i>et al.</i> , 2008
<i>Escherichia coli</i> – ETEC/ Diarrhoea	FaeG (F4 or K88 pigs); FanC (F5 or K99 calves, lambs); GAG (humans);	specific glycoconjugates	brush borders of intestinal enterocytes;	Nagy and Fekete, 1999; Van den Broeck <i>et al.</i> , 2000; Grange <i>et al.</i> , 2002
<i>Escherichia coli</i> - EPEC/ diarrhoea	Bfp; intimin	Phosphatidyletha nolamine; Tir	intestinal epithelium	Hicks <i>et al.</i> , 1998; Nougayrède <i>et al.</i> , 2003; Touze <i>et al.</i> , 2004
<i>Escherichia coli</i> - EHEC/ haemolytic uremic	intimin	Tir	colonic epithelium	Li <i>et al.</i> , 2000; Goosney <i>et al.</i> ,

syndrome				2001; Liu <i>et al.</i> , 2002
<i>Escherichia coli</i> - UPEC/ Pyelonephritis	P pili [PapG (I, II, III)]; FimH, fimbriae	Gb03, Gb04, Gb05; CD55, Gal(α 1-4)Gal containing isoreceptors, mannosylated glycoproteins	kidney epithelial cells, erythrocytes; urinary tract epithelium	Dodson <i>et al.</i> , 2001; Johnson <i>et al.</i> , 2001; Ishikawa <i>et al.</i> , 2004, Nowicki <i>et al.</i> , 2001
<i>Escherichia coli</i> - NMEC/ Neonatal meningitis	SfaII (S fimbriae)	sialyl- α 2-3 β -galactose-containing receptor molecules	endothelial and epithelial cells	Tullus <i>et al.</i> , 1992; Saren <i>et al.</i> , 1999; Bonacorsi <i>et al.</i> , 2000
<i>Escherichia coli</i> O157:H7	flagillin	TLR-5	Human colon epithelium	Miyamoto <i>et al.</i> , 2006
non-typeable <i>Haemophilus influenzae</i> / otitis media, sinusitis, conjunctivitis	HifE (pilus adhesin); HMW1, HMW2; Hap; Hia	fibronectin; α 2-3 linked sialic acid glycoprotein, unknown; fibronectin, laminin, collagen IV; unknown	respiratory epithelium	McCrea <i>et al.</i> , 1997; Laarmann <i>et al.</i> , 2002; St. Geme III 2002; O'Neill <i>et al.</i> , 2003
<i>Haemophilus influenzae</i>	Fimbriae LKP family	Sialic acid-containing lactosyl ceramides and AnWJ antigen	Oropharyngeal epithelial cells and erythrocytes	van Alphen <i>et al.</i> , 1990
<i>Helicobacter pylori</i> / Peptic ulcer disease	BabA, SabAB	MUC5AC, MUC5B and MUC57	Oral cavity and stomach epithelium	Goodwin <i>et al.</i> , 2008; Lindén <i>et al.</i> , 2008
<i>Legionella pneumophila</i> / Legionnaires disease	pilE; pilBCD (type IV pili); MOMP; enhD;	β 2 integrin (CR3), C1q, FcR;	macrophage; monocytes, epithelial cells	Cirillo <i>et al.</i> , 200; Samrakandi <i>et al.</i> , 2002
<i>Listeria monocytogenes</i> / listeriosis	InlA; InlB	E-cadherin; gC1q-R	epithelial cells	Braun <i>et al.</i> , 2000; Kathariou, 2002
<i>Moraxella catarrhalis</i>	UspA1 And UspA2	Fibronectin	Epithelial cell	Tan <i>et al.</i> , 2006
<i>Mycobacterium leprae</i> / leprosy	PGL-1 glycolipid	α 2-laminin-dystroglycan complex	Schwann cells	Marques <i>et al.</i> , 2001; Brophy, 2002
<i>Mycobacterium tuberculosis</i> / tuberculosis	HbhA protein	α _M β ₂ integrin (CR3 or CD11b/CD18)	macrophage	Mueller-Ortiz, 2001; Velasco-Velázquez <i>et al.</i> , 2003
<i>Mycobacterium avium</i> / pulmonary disease	FAP	fibronectin	ECM (damaged epithelial cells)	Schorey <i>et al.</i> , 1996; Middleton <i>et al.</i> , 2000
<i>Mycoplasma pneumoniae</i>	P1; P30	sulfated glycolipids,	respiratory epithelium,	Athamna <i>et al.</i> , 1996; Seto <i>et al.</i> , 2001; Balish <i>et al.</i> , 2003;

atypical "walking" pneumonia		sialylated compounds	alveolar macrophages	Seto and Miyata, 2003
<i>Mycoplasma genitalium</i> , <i>M. pneumoniae</i>	MG: P140 and P110; MP: P1 and P30 (Specific adhesins of attachment organelles)			Burgos <i>et al.</i> , 2006
<i>Neisseria meningitidis</i> / carrier state	pilC (type IV pili); Opa; Opc	CD46; HSPGs, fibronectin, vitronectin	nasopharyngeal epithelium, endothelium	Merz and So, 2000; Dehio <i>et al.</i> , 2000; Hauck and Meyer, 2003;
<i>Porphyromonas gingivalis</i>	Type II fimbriae	$\alpha_5\beta_1$ -integrin		Nakagawa <i>et al.</i> , 2002
<i>Pseudomonas aeruginosa</i>	type IV pili; OprF; PA-IL, PA-IIL	asialo-GM1 - GM2; galactose- and fucose/mannose-containing glycoconjugates	epithelium	Craig <i>et al.</i> , 2004; Azghani <i>et al.</i> , 2002; Winzer <i>et al.</i> , 2000; Imberty <i>et al.</i> , 2004
<i>Rickettsia sp.</i>	rOmpA: Crystalline rOmpA layer (S-layer) made of Surface protein antigen (SPA)		endothelial cells	Li and Walker, 1998
<i>Salmonella enterica</i> serovar Typhimurium/ gastroenteritis	fim (type I fimbriae); pef (PE fimbriae); lpf (LP fimbriae); agf (curli fimbriae); ShdA	oligomannose motifs; Hep-2 domain of fibronectin	intestinal epithelium	Baumler <i>et al.</i> , 1997; Thankavel <i>et al.</i> , 1999; Kingsley <i>et al.</i> , 2004
<i>Shigella flexneri</i> / Dysentery	Invasion plasmid antigen BCD	$\alpha_5\beta_1$ integrin; carbohydrate moieties associated with mucin layer	colonic epithelial cells	Rajkumar <i>et al.</i> , 1998; Kerr, 1999; Kohler <i>et al.</i> , 2002
<i>Staphylococcus aureus</i> / boils, furuncles, impetigo, septic shock	MSCRAMMs (FnBP, Protein A, PNSG, Cna, coagulase, Clf)	$\alpha_5\beta_1$ integrin; other unknown receptors on collagen, fibrinogen, IgG, prothrombin	extracellular matrix,	Shuter <i>et al.</i> , 1996; Salyers and Whitt, 2002; Roche <i>et al.</i> , 2004;
<i>Streptococcus pneumoniae</i> / sepsis, meningitis, otitis media, pneumonia	PavA	fibronectin	nasopharynx and alveolar epithelium	Holmes <i>et al.</i> , 2001
<i>Streptococcus pyogenes</i> / throat infections, other serious infections	MSCRAMMs (SfbI/F1, Fpb54, SfbII/SOF, F2)	$\alpha_5\beta_1$ integrin (fibronectin receptor)	pharyngeal epithelium	Cue <i>et al.</i> , 2000; Towers <i>et al.</i> , 2003; Kreikemeyer <i>et al.</i> , 2004
Group A Streptococcus (<i>S. pyogenes</i>)	Protein M	CD46	Keratinocytes,	Rezcallah <i>et al.</i> , 2005

Group B Streptococcus	BibA	hC4bp	Epithelial cells	Santi <i>et al.</i> , 2007
Group G Streptococcus (<i>S. dysgalactiae</i>)	Surface protein FOG	Collagens I fibrils.		Nitsche <i>et al.</i> , 2006
<i>Treponema pallidum</i> / Syphilis	MSCRAMMs	fibronectin receptor containing α_5 ; laminin receptor	mucosal epithelium	Cameron, 2003; Lee <i>et al.</i> , 2003;
<i>Vibrio cholerae</i> / cholera	Tcp pili; others (O Ag of LPS, MSHA, MFRHA)	specific carbohydrate and glycoprotein receptors	intestinal epithelium	Franzon <i>et al.</i> , 1993; Häse and Mekalanos, 1998; Sasmal <i>et al.</i> , 2002;
<i>Yersinia enterocolitica</i> / diarrhoea	invasin (OMP); YadA	β_1 integrins ($\alpha_3\beta_1$, $\alpha_4\beta_1$ $\alpha_5\beta_1$ $\alpha_6\beta_1$ and $\alpha_v\beta_1$); collagen, laminin, fibronectin	intestinal epithelium and submucosa	Schulte <i>et al.</i> , 2000; El Tahir and Skurnik, 2001; Isberg and Barnes, 2001;

asialo-GM1 -GM2: glycolipids

Bfp: bundle forming pili

C4bp: complement component 4 binding protein

CD46: membrane cofactor protein, member of superfamily of complement resistant proteins

CD55: decay accelerating factor for complement

Clf: clumping factor

Cna: collagen binding protein

CR1: complement receptor type 1

CR3: complement receptor type 3

Curli fimbriae: thin aggregative fimbriae

ECM: extracellular matrix

EHEC : Enterohemorrhagic *Escherichia coli*

EPEC : Entero-pathogenic *Escherichia coli*

ETEC : Enterotoxigenic *Escherichia coli*

FAP: fibronectin attachment protein

FcR: Fc receptor

FHA: filamentous hemagglutinin

FnBP: fibronectin binding protein

FOG: Friend of GATA

HbhA: heparin-binding hemagglutinin

HSPGs: heparansulphate proteoglycans

InlA: internalin A

InlB: internalin B

LP fimbriae: long polar fimbriae

LPS: lipopolysaccharide

LRI/IAP: leukocyte response integrin ($\alpha V\beta 3$, CD61) / integrin associated protein (CD47)

MFRHA: mannose fucose resistant hemagglutinin

MOMP: major outer membrane protein

MSCRAMMS: microbial surface components recognising adhesive matrix molecules

MSHA: mannose sensitive hemagglutinin

MUC: mucin gene

NMEC : Neonatal Meningitidis *Escherichia coli*

OMP: outer membrane protein

Opa: opacity associated

Opc: class 5 outer membrane protein

OprF: porin F

PavA: Adherence and virulence protein A

PE fimbriae: plasmid-encoded fimbriae

PGL-1: phenolic glycolipid 1

PNSG: Poly-n-succinyl- β -1,6 glucosamine

rOmpA: 190-kDa cell surface antigen

SfbI: streptococcal fibronectin-binding protein I

SfbII: streptococcal fibronectin-binding protein II

ShdA: host colonization factor

Tcp: toxin co-regulated pili (demonstrably important in humans)

Tir: Translocated intimin receptor

TLR-5: Toll-like receptor 5

UspA: ubiquitous surface protein

UPEC : Uropathogenic *Escherichia coli*

VLA-5: very late antigen-5

24. Many micro-organisms used for industrial purposes have elaborate properties and extensive biotechnological applications. For example, *Rhodococcus* spp., have elaborate adhesive properties for attachment to environmental surfaces or for biofilm formation that are particularly useful for adherence to heavy metals and hydrocarbons (Shabtai and Fleminger, 1994; Stratton *et al.*, 2002). Although *Rhodococcus* spp. are not generally considered to be human pathogens, some species have emerged as rare opportunistic human pathogens. *Rhodococcus equi* infection is characterised by bronchiopneumonia following adherence and entry into alveolar macrophages. Garton *et al.* (2002) postulate that a novel lipoarabinomannan (LAM) variant may contribute to pathogenesis of disease caused by *R. equi.*, similar to ManLAM of *Mycobacterium tuberculosis* which facilitates adherence to alveolar macrophages via mannose receptors. Evaluators must always be cognisant that those factors which have extensive industrial applications (for instance, adhesive properties) may also confer one of the properties that allow a micro-organism to cause disease in susceptible individuals.

25. In addition to determining pathogen location, adhesins affect important aspects of the biology of infection. Many pathogens have evolved the ability to adhere to cell adhesion molecules (CAMs) which are eukaryotic cell-surface receptors that facilitate cell interaction and communication with other cells and the ECM. In these cases, cell signalling processes involving actin rearrangements are affected by virtue of their contact with the cytoskeleton (Mims *et al.*, 2001). Host cell adhesion receptors can be subdivided into several groups, for example, integrins, cadherins, immunoglobulin superfamily cell adhesion molecules (IgCAMs), selectins, receptor protein tyrosine phosphatases, syndecans and hyaluronate receptors (Freemont, 1998; Hauck, 2002). Since multiple adhesion molecules are found on a single host cell, they are ideal targets for pathogens trying to anchor themselves. Mimicry of host cell receptors and ligands allow bacteria to exploit several of these molecules to establish tight contact with eukaryotic cell surfaces and the ECM (Hauck, 2002; Boyle and Findlay, 2003).

26. Bacterial adhesins have been divided into two major groups: 1) pili (fimbriae)³ and 2) non-pilus (afimbrial) adhesins. Pili and fimbriae are interchangeable terms to designate short hairlike structures on the surface of bacterial cells. For the purposes of this document, the terms will be used interchangeably and will depend upon the article referenced.

27. Many bacteria express adhesive pili which are hairlike surface appendages extending out from the bacterial surface to establish contact with the surface of the host cell. Pili may be displayed circumferentially (Salyers and Whitt, 2002; Hardy *et al.*, 2003) or preferentially located on one part of the bacterial cell (Nougayrède *et al.*, 2003). Binding to the host cell-target is specific and it is this specificity that determines the preferential site/host for adherence.

28. The P pilus operon serves as a useful model for the general study of different bacterial pilus systems since the concepts are similar and many of the components are interchangeable even though the host receptors differ. For example, the PapD chaperone, in addition to mediating the assembly of P pili, can modulate the assembly of type 1 pili (Bonci *et al.*, 1997). There is a family of periplasmic PapD-like chaperones needed for the assembly of several pili, including K88, K99 and *Haemophilus influenzae* pili. Additionally, since the molecular machinery required for pilus biogenesis and bacterial surface assembly is conserved among diverse pili (Hultgren *et al.*, 1993) the operons of type 1 and P pili are very similar with alignment of functionally analogous sequences. Nevertheless, they are structurally distinct pili (type I are

3. Whether to use the term pili or fimbriae has caused much debate. In 1955, fimbriae were first described by Duguid *et al.* Sometime thereafter Brinton (1959) published similar findings but had called the structures pili. This led to an acrimonious exchange of letters in the scientific press as to the correct terminology, however, it has yet to be unequivocally settled.

flexible, rod-like fibres, while P pili are rigid structures) and bind to different receptors (Finlay and Falkow, 1997). Many adhesins of *E. coli* include their common pili and many strains of *E. coli* are able to express a variety of pili encoded by distinct regions of the chromosome or plasmids (Johnson, 1991). This genetic diversity permits a bacterium to adapt to a changing environment and exploit a variety of niches presented by different host surfaces. Indeed, different pilin sequences may lead to tissue tropism for adherence and distinct invasion capacities into epithelial cells.

29. Type 1 pili produced by *E. coli* strains recognise mannose receptors on host cells (Schwan *et al.*, 2002). The mannose binding site may be located at the tips or inserted along the length of the pilus. By genetically altering the tip protein adhesin, bacteria can gain ability to adhere to different receptors. This is of specific interest for evaluators since changes to tip proteins can significantly alter the tropism of the bacteria for a specific receptor. For example, tip proteins on pyelonephritis-associated (pap) pili recognise a galactose-galactose disaccharide, while tip proteins on S-fimbriae recognise sialic acid. It is equally important to recognise that while a receptor may be cell- or host-specific, this specificity may also change as the host matures. Thus, while *E. coli* has been associated with meningitis in the neonate, in the adult this association is lost. Animal studies have demonstrated that endothelial receptors for *E. coli* are only present in the brain of the newborn (Parkkinen *et al.*, 1988).

30. Type 4 pili (Tfp) constitute a separate, unique class of pili expressed by diverse Gram-negative organisms of medical, environmental and industrial importance including *Pseudomonas aeruginosa*, *Neisseria* spp., *Moraxella* spp., Enteropathogenic *E. coli* (EPEC), and *Vibrio cholera*. Tfp share structural, biochemical, antigenic and morphological features (Strom and Lory, 1993) and a biogenesis pathway that is highly conserved and resembles the type II protein secretion pathway (Wolfgang *et al.*, 2000). It has been suggested that the pilin molecules located at the tip may function as the adhesins since the sequences exposed differ from those packed into repeating structures within a pilus. For instance, Tfp-mediated adherence is strongly correlated with a separate tip protein, PilC for *N. gonorrhoeae*, rather than the more abundant pilin subunit protein PilE (Winther-Larsen *et al.*, 2001). Alterations in the pilus subunit can also affect adherence levels. Whereas, *P. aeruginosa* strains usually express only one pilus subunit, the considerable variation exhibited by this subunit among strains affects the proficiency of adherence.

31. Bacteria usually adhere to receptor molecules via protein structures on their cell surface (typically pili) with distinct surface-binding capacities (Soto and Hultgren, 1999). However, other important adhesins found in a number of Gram-negative pathogens may, alternatively, be anchored directly to the outer membrane, resulting in an intimate attachment with the target cell receptor (Veiga *et al.*, 2003). Afimbrial adhesins are bacterial surface proteins, structurally distinct from the adhesins of fimbriae, that facilitate the tighter binding of bacteria to host cell that usually follows initial binding via fimbriae. These proteins are important components of the systems that allow bacteria to attach to and invade host cells. Some may recognise proteins on host cell surfaces while others recognise carbohydrates (Salyers and Whitt, 2002). *Legionella pneumophila* afimbrial adhesin seems to be involved in attachment to and invasion of amoebae. Adhesins require presentation on the bacterial surface in an active binding conformation for interaction with the host cell. In Gram-negative bacteria, surface localisation requires the translocation of the protein through the cytoplasmic membrane (export into the periplasm) and through the outer membrane (secretion). Generally, surface localisation occurs via one of five different secretion pathways distinguished at least in part by the mechanisms of translocation across the outer membrane and designated types I-V (Stathopoulos *et al.*, 2000).

32. Proteins secreted by the type V pathway are referred to as autotransporters (Henderson, *et al.*, 2000). For example, the *H. influenzae* Hap autotransporter is a non-pilus adhesin that influences adherence to epithelial cells and some extracellular matrix proteins and impacts bacterial aggregation and microcolony formation. Other autotransporter proteins that function as adhesins include: ShdA and MisL of *Salmonella enterica* (Kingsley *et al.*, 2002); Pertactin, Vag8 and TcfA of *Bordetella* spp. (Li *et al.*,

1992; Finn and Stevenson., 1995; Finn and Amsbaugh, 1998); AIDA-I, TibA and Ag43 of *E. coli* (Benz and Schmidt, 1989; Lindenthal and Elsinghorst, 1999; Kjaergaard *et al.*, 2000; Henderson and Owen, 1999); Hap, Hia and Hsf of *H. influenzae* (St. Geme III *et al.*, 1994; Barenkamp and St. Geme III, 1996; St. Geme III *et al.*, 1996; Yeo *et al.*, 2004); BabA of *H. pylori* (Ilver *et al.*, 1998); UspA2, UspA2h of *Moraxella catarrhalis* (Aebi *et al.*, 1997; Lafontaine *et al.*, 2000) and rOmpA of *Rickettsia* spp. (Crocquet-Valdes *et al.*, 1994).

33. The autotransporter (AT) secretion systems is a modular structure consisting of three domains. These include a C-terminal transporter or β domain, an internal passenger domain and an N-terminal signal sequence. The β -domain ends up being inserted as an oligomer in the OM while the passenger domain is the protein moiety eventually presented on and anchored to the cell surface (Henderson *et al.*, 1998; Veiga *et al.*, 2003; Desvaux *et al.*, 2004). The AT secretion system is tolerant to a number of diverse protein structures which favours the emergence of novel adhesins with new specificities. Veiga *et al.*, 2003, have demonstrated this property by creating hybrid fusion proteins containing the β -AT domain of an AT protein of *Neisseria gonorrhoeae* and the partner leucine zippers of eukaryotic transcription factors Fos and Jun. When the hybrid proteins were expressed in *E. coli*, the cells acquired novel adherence traits resulting in the self-association and clumping of planktonic bacteria in liquid media, or in formation of stable consortia between cells of strains expressing the dimerisation domains.

34. Another type of adherence of particular importance to risk analysis is bacterial attachment to a surface and each other to form a biofilm. In this case the adherence is mediated by an extracellular polysaccharide slime that acts as a kind of glue to bind the bacteria to each other and to a surface (Salyers and Whitt, 2002).

35. Many microbes can occupy a variety of ecological niches, whereas others are confined to a specific microenvironment. The range of hosts, tissues or cell types colonised by bacteria is determined, in part, by adhesin recognition of and affinity for host receptors. For example, most *Bordetella* spp. can cause a similar disease in the upper respiratory tract of many mammals but their host specificities can differ considerably. *B. pertussis* is human specific while *B. bronchisepta* is responsible for infecting a wide variety of mammals and birds but only rarely causes disease in humans. Strains of *B. parapertussis* can be divided into two groups, one which is human specific, the other ovine specific (Cummings *et al.*, 2004).

36. While not an all-inclusive list, Table I gives examples of specific attachments of micro-organisms to host cell surfaces. It should be noted that many, but not all, adherence factors also play a role in invasion. For a more comprehensive review of adhesins, receptors and related structures, the reader is directed to articles by Connell *et al.*, 1997; Soto and Hultgren, 1999; Klemm and Schembri, 2000; Nougayrede *et al.*, 2003.

II.2 Host Invasion

37. Subsequent to attachment the bacterium may or may not invade the host, depending upon the pathogen. In any case, the host-associated bacterium must now repel the host defenses. Infection is the invasion of the host by microorganisms, which then multiply in close association with the host's tissues. Mechanisms that enable a bacterium to invade eukaryotic cells make entry possible at mucosal surfaces. Whereas some invasive bacteria are obligate intracellular pathogens, most are facultative intracellular pathogens. In many cases, the exact bacterial surface factors that mediate invasion are not known, and multiple gene products are frequently involved. Pathogens may have mechanisms to disguise or switch antigens on their surface, thus confusing humoral and cellular immunity. Defensive mechanisms include the expression of proteins and enzymes to destroy phagocytes and weaken surrounding host tissues, making it easier to spread to new areas. Many pathogens have also developed resistance to common antibiotics, allowing them to continue infection even after treatment.

38. Entry into tissues may take several forms. Micro-organisms may pass directly through the epithelia, especially mucous membranes that consist of a single cell layer. However in the case of skin, which is tough and multilayered, access is usually via trauma, insect bites or other damage to the surface.

39. Invasion through mucosal surfaces requires that the bacteria first cross the mucus layer coating the epithelium and then adhere to and infect the underlying target tissue. Many micro-organisms must first interact with specific receptors on the surface of the host cell to penetrate through mucosal epithelia. Mucosal and submucosal glands secrete a protective network of carbohydrate-rich glycoproteins called mucin. Aside from the lubricative value of mucin, the primary function is to trap bacteria and prevent them from gaining access to mucosal cells. Whereas most bacteria have mucin-binding surface molecules and are removed with the mucus flow, some establish residence within the mucus layer or penetrate the mucus and adhere to epithelial cells (Salyers and Whitt, 2002). Bacteria which lack mucin-binding surface proteins or carbohydrates may have the ability to transit the mucin layer. Since mucin is an extremely viscous material that is relatively resistant to enzymatic digestion (de Repentigny *et al.*, 2000; Moncada *et al.*, 2003) bacteria that are able to move through viscous material or degrade mucin can overcome the first major barrier to mucosal invasion. In risk evaluation attention must be given, in general, to any changes in surface proteins or carbohydrate moieties involved in binding to mucin or with an ability to degrade mucin.

40. In most cases, once a micro-organism crosses an epithelial barrier, it is recognised by macrophages (mononuclear phagocytes and neutrophils) resident in tissues. Binding to specific cell-surface receptors triggers phagocytosis. When internalised bacteria become enclosed in a membrane vesicle or phagosome, it becomes acidified by the lysozymes. Fusion with lysosomes mediates an intracellular antimicrobial response to kill the bacteria. Most bacteria are destroyed by this process, however, there are various bacterial strategies for coping with phagolysosome formation and evading destruction. One strategy prevents phagosome-lysosome fusion and is used by *Mycobacterium*, *Legionella* and *Chlamydia* spp. Another strategy exemplified by *Actinobacillus* spp., *Listeria* spp., *Rickettsia* spp. and *Shigella* spp. involves disruption of the vesicle membrane and entry into the cytoplasm (Gouin *et al.*, 1999). Bacterial survival and evasion of host response will be covered in more detail under the heading “Multiplication in Host and Evasion of Host Immune Response”.

41. Host invasion may be aided by the production of invasins which act against the host by breaking down primary or secondary defenses of the body. Part of the pathology of a bacterial infection may be the result of invasive activity. One of the best-studied invasins is produced by *Yersinia* spp. Isberg and Leong, (1990) demonstrated that invasin tightly adheres to β_1 integrins (host cell adhesion receptors) to mediate bacterial uptake by “zippering” the host cell membrane around the bacterium as it enters. The ability of various bacteria to induce internalisation following contact with eukaryotic cells appears to play a crucial role in pathogenesis (Finlay and Cossart, 1997). This uptake is directed into host cells that are not naturally phagocytic, including epithelial and endothelial cells lining mucosal surfaces and blood vessels, and is manipulated by the invading bacteria.

42. The two main mechanisms of induced uptake are zipper and trigger. Bacteria utilizing the zipper mechanism of entry express a surface protein which binds to host surface receptors involved in cell-matrix or cell-cell adherence. This directed contact between the bacterial ligands and cellular receptors proceeds sequentially inducing host membrane extension and bacterial uptake through a “zippering” mechanism. (Cossart and Sansonetti, 2004). Various pathogens such as *Helicobacter pylori* (Kwok *et al.*, 2002), *Listeria monocytogenes* (Lecuit *et al.*, 1997), *Neisseria* spp. (McCaw *et al.*, 2004) and some streptococci (Dombek *et al.*, 1999) use this type of mechanism. With the trigger mechanism of entry, bacteria bypass the first step of adhesion and interact directly with the cellular machinery. Effectors are injected through a type III secretory system (TTSS) and the bacterial signals sent to the host cell induce prominent membrane ruffling and cytoskeletal rearrangements resulting in macropinocytosis and almost passive entry of bacteria (Finlay and Cossart, 1997). This type of system is used by *Salmonella* spp. (Hayward *et al.*, 2002) and

Shigella flexneri (Van Der Goot *et al.*, 2004). Generally, invasion into normally non-phagocytic cells establishes a protected cellular niche for bacterial replication, survival and persistence.

43. It must be stressed that a single invasion strategy may not be used by all members of a species. *Streptococcus pyogenes* strains have been shown to trigger different uptake events via distinct mechanisms. For instance, in *S. pyogenes* strain A40, the protein SfbI has been shown to be the main factor for attachment and invasion and uptake is characterised by the lack of actin recruitment and the generation of large membrane invaginations (Molinari *et al.*, 1997). Whereas in *S. pyogenes* strain A8, the *sbfl* gene is absent and uptake involves major rearrangements of cytoskeletal proteins leading to recruitment and fusion of microvilli and the generation of cellular leaflets (Molinari *et al.*, 2000).

44. There is little distinction between the extracellular proteins which promote bacterial invasion and various extracellular protein toxins or exotoxins which damage the host. The action of an invasin is usually proximal to the site of bacterial growth and may not kill the cells in its range of activity, whereas exotoxins may act at sites distant to those of bacterial growth and are usually cytotoxic. In general, exotoxins are more targeted and result in greater pathology than invasins (Henderson *et al.*, 1996; Al-Shangiti, 2004). However, some exotoxins such as diphtheria toxin or anthrax toxin play a role in invasion while some invasins (*e.g.*, staphylococcal leukocidin) have a relatively specific cytopathic effect. Table II lists some extracellular proteins which act as invasins. Host damage by exotoxins is more fully discussed under the heading Ability to Damage or Kill Host.

II.3 Evasion of Host Immune Response & Multiplication in Host

45. Microbial infections rarely cause disease without first multiplying within the host. The exception is for bacterial toxins; while they do lead directly to disease, they do not multiply and hence are toxicants not infections. Usually, multiplication is the main cause of disease associated with bacterial infection. Following entry into a host cell, most bacteria, including pathogens, are killed by macrophages and polymorphonuclear leukocytes (PMNs). The incubation period reflects the time needed for the bacteria to overcome these early defenses and increase in number. Since the success of many pathogens relies on their ability to circumvent, resist or counteract host defense mechanisms, pathogens have developed numerous ways to avoid and manipulate host responses. This is reflected in the constant evolution of host defenses and bacterial pathogenic mechanisms.

Table 2. Extracellular bacterial proteins that act as invasins

Invasin	Bacteria	Action	Reference
C5a peptidase	Group A and B Streptococcus	Inactivates human C5a and promotes epithelial cells invasion leading to the dissemination of bacteria	Wexler <i>et al.</i> , 1985; Cheng <i>et al.</i> , 2002
collagenase	<i>Clostridium</i> spp.	dissolves collagen	Borriello, 1998; Poilane <i>et al.</i> , 1998
Gingipain (cystein protease)	<i>Porphyromonas gingivalis</i>	Destruction of connective tissue, degradation of paxillin and FAK	Nakagawa <i>et al.</i> , 2006
HAD superfamily member SerB653	<i>Porphyromonas gingivalis</i>	Secreted when in contact with gingival epithelial cells	Tribbble <i>et al.</i> , 2006
hyaluronidase	<i>Streptococcus</i> spp., <i>Staphylococcus</i> spp. and <i>Clostridium</i> spp.	degrades hyaluronic acid of connective tissue	Paton, <i>et al.</i> , 1993; Borriello, 1998; Hynes, 2000.
hemolysins/ cytolysins (see also lecithinases and phospholipases)	<i>Edwardsiella tarda</i> , <i>Escherichia coli</i> , <i>Bordetella pertussis</i> , <i>Listeria monocytogenes</i> , <i>Streptococcus</i> spp., <i>Staphylococcus</i> spp. and <i>Clostridium</i> spp..	destroy red blood cells and other cells by lysis	Paton <i>et al.</i> , 1993; Strauss <i>et al.</i> , 1997; Bassinet <i>et al.</i> , 2000; Cockeran <i>et al.</i> , 2002; Doran <i>et al.</i> , 2002; Nizet, 2002; Seirig <i>et al.</i> , 2003;
kinases	<i>Staphylococcus</i> spp.. and <i>Streptococcus</i> spp..	converts plasminogen to plasmin which digests fibrin	Ringdahl <i>et al.</i> , 1998; Gladysheva <i>et al.</i> , 2003;
lecithinases	<i>Clostridium perfringens</i> , <i>Listeria monocytogenes</i>		Awad <i>et al.</i> , 1995; Appelberg & Leal, 2000;
leukocidin	<i>Staphylococcus aureus</i>	disrupts neutrophil membranes and causes discharge of lysosomal granules	Rogolsky, 1979; Dinges <i>et al.</i> , 2000
phospholipases	<i>Clostridium perfringens</i> , <i>Neisseria gonorrhoeae</i> , <i>Shigella flexneri</i> , <i>Pseudomonas aeruginosa</i>	hydrolytic enzymes involved in phospholipid cleavage	Vasil, 1986; Awad <i>et al.</i> , 1995; Meyer <i>et al.</i> , 1997; Guhathakurta <i>et al.</i> , 1999; Edwards <i>et al.</i> , 2003;
sialidases/ neuraminidases	<i>Vibrio cholerae</i> , <i>Shigella dysenteriae</i> , <i>Streptococcus pneumoniae</i> , <i>Trichomonas</i>	degradation of sialomucin on epithelial cell layer	Paton <i>et al.</i> , 1993; Wiggins <i>et al.</i> , 2001; Stewart-Tull <i>et al.</i> , 2004;

	<i>vaginalis</i> , <i>Bacteroides fragilis</i> , <i>Gardnerella vaginalis</i> , <i>Mycoplasma hominis</i>		
--	---	--	--

46. Phagocytes are the first line of defense encountered by bacteria following tissue invasion. Phagocytosis has two main functions: 1) disposal of microbial pathogens and 2) antigen processing and presentation for the induction of specific immune responses. Bacteria that readily attract phagocytes and are easily ingested and killed are generally unsuccessful pathogens. In contrast, most successful pathogens interfere to some extent with the activities of phagocytes or in some way avoid their attention. Bacterial pathogens have devised numerous and diverse strategies to avoid phagocytic engulfment and killing, with most strategies aimed at blocking one or more of the steps in phagocytosis, thereby halting the process. Other bacterial pathogens, exemplified by *Brucella* spp., *Mycobacterium* spp., and *Legionella* spp., survive and proliferate within "professional" phagocytes such as macrophages, neutrophils and dendritic cells. Survival inside of phagocytic cells, in either neutrophils or macrophages, protects the bacteria from antibodies, antibiotics, bacteriocides, etc. during the early stages of infection or until they develop a full complement of virulence factors.

47. Phagocytosis comprises several steps:

- Recognition and attachment of bacteria to professional (macrophages/neutrophils) or non-professional phagocytes (e.g. epithelial cells). The recognition is usually receptor-mediated (e.g. opsonisation - Fc receptors) but can be non-specific (bulk fluid pinocytosis);
- Endocytic entry of bacteria into the phagocytic cell with the generation of a phagocytic vacuole (endosome, phagosome);
- Generation of a phagolysosome via fusion of the phagosome with primary and secondary lysosomal granules;
- Degranulation and killing through the release of lysosomal or granular contents in direct apposition to the bacteria within the phagolysosome (maybe via oxygen dependent and/or oxygen-independent mechanisms of killing).

48. The various strategies employed by bacteria to avoid destruction by phagocytes include: 1) adapting to withstand the antimicrobial activity of the fused phagolysosome; 2) altering phagocytosis to target the bacterium to a novel phagosome; 3) escape from the phagosome into the cytosol by lysing the vacuolar membrane; 4) blocking lysosome/phagosome fusion or attenuating the acidification of phagolysosomes; 5) circumventing or resisting phagocytosis.

1) Adapting to withstand the antimicrobial activity

49. With some intracellular bacteria, phagosome-lysosome fusion occurs, but the bacteria are resistant to inhibition and killing by the lysosomal constituents. Also, some extracellular pathogens can resist killing in phagocytes utilizing similar resistance mechanisms. Resistance to phagocytic killing within the phagocytic vacuole is not completely understood but it may be due to the surface components of the bacteria or due to extracellular substances produced which interfere with the mechanisms of phagocytic killing. *Brucella abortus* and *Staphylococcus aureus* are vigorous catalase and superoxide dismutase producers, which might neutralise the toxic oxygen radicals that are generated by the NADPH-oxidase and myeloperoxidase systems in phagocytes. *S. aureus* also produces cell-bound pigments (carotenoids) that "quench" singlet oxygen produced in the phagocytic vacuole. There are some microorganisms, however,

that are dependent upon phagosome-lysosome fusion for intracellular replication and persistence. The pH that develops in the phagosome after engulfment induces bacterial gene products that are essential for their survival in macrophages. For instance, the replication and synthesis of metabolic factors required for intracellular persistence of *Coxiella burnetii*, *Brucella suis* and *S. typhimurium* is induced by the acidic pH found within the phagolysosome (Hackstadt and Williams, 1981; Rathman *et al.*, 1996; Porte *et al.*, 1999; Ghigo *et al.*, 2002).

2) Alteration of phagocytosis

50. Bacteria such as *Salmonella* spp. are able to induce phagocytosis in non-professional phagocytes. The *Salmonella*-containing vacuole (SCV), a unique cytoplasmic organelle formed following phagocytic induction, actually protects the bacterium; *Salmonella* spp. interfere with the ability of this phagosome to fully mature into a phagolysosome (Duclos and Desjardins, 2000).

3) Escape

51. Escape from the phagosome is a strategy employed by the Rickettsiae. *Rickettsia* spp. enter host cells in membrane-bound vacuoles (phagosomes) but are free in the cytoplasm a short time later, perhaps in as little as 30 seconds. A bacterial enzyme, phospholipase A, may be responsible for dissolution of the phagosome membrane. *Listeria monocytogenes* relies on several molecules for early lysis of the phagosome to ensure their release into the cytoplasm. These include listerolysin O (LLO), a cholesterol-dependent cytolysin (CDC) and two forms of phospholipase C. The low optimal pH activity of LLO allows the bacterium to escape from the phagosome into the host cytosol without damaging the plasma membrane of the infected cell.

52. Glomski *et al.* (2002) demonstrated that a single amino acid change from leucine 461 to threonine profoundly increased the hemolytic activity of LLO at a neutral pH and promoted premature permeabilisation of the infected cells. This discovery demonstrates how minor changes in proteins can be used by bacterial pathogens to establish and maintain the integrity of their specific niches or exploited by researchers working with bacteria to produce a protein with novel properties. Once in the cytoplasm, *Listeria* spp. induces its own movement through a process of host cell actin polymerisation and formation of microfilaments within a comet-like tail. *Shigella* spp. also lyses the phagosomal vacuole and induces cytoskeletal actin polymerisation for the purpose of intracellular movement and cell-cell spread. This highlights the fact that evaluators should consider whether changes in proteins affect the virulence of an organism.

Table 3: Bacterial proteins that act as immunomodulator

Bacteria/ Disease	Immunomodulator	Action	Reference
<i>Borrelia burgdorferi</i> /Lyme disease	OspE	Binds factor H	McDowell <i>et al.</i> , 2004
<i>Enterococcus faecalis</i>	Capsular polysaccharide	Resistance to opsonophagocytic killing	Hancock and Gilmore, 2002
<i>Francisella tularensis</i> /tularemia	?	Survive and multiply inside macrophages	Maier <i>et al.</i> , 2007
<i>Streptococcus pneumoniae</i>	PspA	Inhibitor of factor B mediating complement activation and opsonisation	Tu <i>et al.</i> , 1999

Group A Streptococcus (<i>S. pyogenes</i>)	Fba	Bind factor H and fH-like protein, contribute to phagocytosis resistance	Wie <i>et al.</i> , 2005
	Protein M	Alteration of opsonophagocytosis by recruitment of factor H	Jarva <i>et al.</i> , 2003
Group B Streptococcus (GBS)	Capsule	Protects from opsonisation by C3. β -protein binds factor H	Rubens <i>et al.</i> , 1987; Jarva <i>et al.</i> , 2003
	CspA (serine protease-like)	Evasion of opsonophagocytosis	Harris <i>et al.</i> , 2003
<i>Listeria monocytogenes</i>	Lysterio-lysin O	Evasion of phagosome	Schnupf and Portnoy, 2007
<i>Neisseria gonorrhoea</i>	Por 1A	Bind factor H, C4 bp, mediate serum resistance	Ram <i>et al.</i> , 1998 and 2001
<i>Neisseria meningitidis</i>	Bind factor H	Avoid lysis by complement system	Schneider <i>et al.</i> , 2006
<i>Staphylococcus aureus</i>	Secretes Extracellular adheran protein (EAP)	Binds to ICAM-1, fibrinogen, vitronectin resulting in the disruption of the leukocyte recruitment	Athanasopoulos <i>et al.</i> , 2006
<i>Yersinia sp.</i>	Yop E, T A, H and Yop J	Block phagocytosis and suppress inflammatory mediators	Fällman and Gustavsson, 2005
<i>Yersinia enterocolica</i>	YadA	Alteration of opsonophagocytosis by recruitment of factor H	China <i>et al.</i> , 1993

4) Blocking fusion or attenuating acidification

53. Some bacteria survive inside of phagosomes by blocking fusion of the phagocytic lysosomes (granules) with the phagosome thus preventing the discharge of lysosomal contents into the phagosome environment. This strategy is employed by *Salmonella* spp., *M. tuberculosis*, *Legionella* spp. and the chlamydiae. With *Legionella* spp., it is known that a single gene is responsible for the inhibition of phagolysosomal fusion. Attenuating the acidification of phagolysosomes is observed with *Rhodococcus* spp. Toyooka *et al.*, (2005) demonstrated that phagolysosomes did not acidify when they contained virulent *R. equi* organisms. Their research indicated that *R. equi* in phagolysosomes produced substance(s) to suppress acidification. Results by Tsukano *et al.* (1999) indicated that inhibition of phagosomal acidification by *Y. pseudotuberculosis* was due to attenuation of vacuolar-ATPase activity.

5) Phagocytic circumvention

54. Bacteria may avoid phagocytosis by simply penetrating areas inaccessible to phagocytes such as the lumens of glands and the urinary bladder and surface tissues such as the skin. Other strategies for phagocyte evasion include suppression of the inflammatory response and inhibition of phagocyte chemotaxis. For example, pneumolysin (streptolysin) toxin produced by *Streptococcus pneumoniae* (Paton and Ferrante, 1983; Ernst, 2000) and components of *Mycobacterium* spp. inhibit polymorphonuclear leukocyte (PMN) migration. Also, studies involving pathogen-induced PMN alterations have suggested that *Anaplasma phagocytophilum* delays PMN apoptosis and lessens proinflammatory cytokine release (Yoshiie *et al.*, 2000; Klein *et al.*, 2000.). Bacteria using host cell mimicry for phagocytic evasion cover their surface with a component which is recognised as "self" by the host phagocytes and immune system. This effectively hides the antigenic surface of the bacterial cell. Phagocytes are unable to recognise bacteria upon contact and thus opsonisation by antibodies to enhance phagocytosis is minimised. For example, *Staphylococcus aureus* produces cell-bound coagulase which clots fibrin on the bacterial surface,

Treponema pallidum binds fibronectin to its surface, while Group A streptococci synthesise a capsule composed of hyaluronic acid which forms the ground substance of host connective tissue. Resistance to phagocytic ingestion is usually due to a component of the bacterial cell surface (cell wall, or fimbriae, or a capsule). Examples of antiphagocytic substances on the bacterial surface include: Polysaccharide capsules (*S. pneumoniae*, *Haemophilus influenzae*, *Treponema pallidum* and *Klebsiella pneumoniae*); M protein and fimbriae of Group A streptococci; Polysaccharide produced as biofilm by *Pseudomonas aeruginosa*; O polysaccharide associated with lipopolysaccharide (LPS) of *E. coli*; K or Vi antigens (acidic polysaccharides) of *E. coli* and *Salmonella typhi*, respectively; Cell-bound or soluble Protein A produced by *Staphylococcus aureus* which attaches to the Fc region of IgG and blocks the cell-binding domain of the antibody. Whereas phagocytic resistance and intracellular proliferation is accomplished via surface components, such as bacterial capsules and LPS, which effectively shield the bacteria, resistance to many bactericidal components of host tissues is usually a function of some structural property. For example, the poly-D-glutamate capsule of *Bacillus anthracis* protects the organisms against the action of cationic proteins (defensins) or by conventional proteases in sera or in phagocytes (Fouet and Mesnage, 2002). Similarly, the outer membrane of Gram-negative bacteria serves as a permeability barrier that is not easily traversed by hydrophobic compounds harmful to the bacteria, for example bile salts of the GI tract. Intact LPS of Gram-negative pathogens may protect the cells from complement-mediated lysis or the action of lysozyme. The outer membrane and capsular components of Gram-negative bacteria (e.g. *Salmonella* spp., *Yersinia* spp., *Brucella* spp., *E. coli*) can protect the peptidoglycan layer from the lytic activity of lysozyme (Hughey and Johnson, 1987; Martinez *et al.*, 1995). Mycobacteria (including *M. tuberculosis*) have waxy, hydrophobic cell wall and capsule components (mycolic acids), which are not easily attacked by lysosomal enzymes (Gao *et al.*, 2003). Other factors that enhance intracellular survival include bacterial enzymes which neutralise oxygen radicals and secreted proteolytic enzymes which degrade host lysosomal proteins. Another strategy in defense against phagocytosis is direct attack by the bacteria upon the professional phagocytes. Most of these are extracellular enzymes or toxins that kill phagocytes either prior to or after ingestion and are discussed under III.4, Ability to Damage or Kill host.

6) Multiplication in Host

55. Multiplication in the host also requires that the micro-organism obtain the necessary nutrients and factors needed for growth and replication. Iron is an essential nutrient that is usually limited within eukaryotic hosts. Many pathogenic bacteria have developed regulated networks of genes important for iron uptake and storage. Also, available iron concentration may trigger the regulation of virulence gene expression (Merrell *et al.*, 2003). *Salmonella* spp. and *E. coli* produce siderophores (extracellular iron-binding compounds) which extract Fe³⁺ from lactoferrin (or transferrin) and supply iron to cells for growth. Successful intracellular lifestyle is conditional on the ability of the bacteria to obtain essential nutrients from the hostile phagosomal environment. For example, the virulence of both *M. tuberculosis* and *Salmonella enterica* (Hingley-Wilson, 2003) is dependent upon their ability to acquire magnesium while inhabiting the phagosome.

II.4 Ability to Damage or Kill Host

56. To counter infection the human host relies, initially, on the innate immunity system. Prior to mounting an immune response, however, the host must first detect the pathogen. The innate immune system uses sets of recognition molecules, called pattern recognition receptors (PRRs). The Toll-like receptors (TLRs) are one of the most important pattern recognition receptor families (Armant and Fenton, 2002). PRRs bind conserved molecular structures, unique to micro-organisms, termed pathogen-associated molecular patterns (PAMPs). PAMPs such as peptidoglycan, teichoic acids, LPS, mycolic acid, and mannose, bind to PRRs on a variety of defense cells of the body causing them to synthesise and secrete a variety of cytokines. These cytokines can, in turn promote innate immune defenses such as opsonisation,

activation of proinflammatory signaling cascades, phagocytosis, activation of the complement and coagulation cascades, and apoptosis (Wilson *et al.*, 2002).

57. The host immune response plays a critical role in determining disease manifestations of chronic infections. Inadequate immune response may fail to control infection, although in other cases the specific immune response may be the cause of tissue damage and disease. Not infrequently, host defense mechanisms go overboard and it is this overaggressive immune response which contributes to the tissue damage observed with some infections. This document however, will focus on specific bacterial factors directly responsible for tissue damage or host death.

58. Bacteria produce a large number of cell-associated or secreted proteins which play a role in colonisation, infection and subsequent tissue damage. The great majority of bacterial virulence factors are secreted products that augment the survival of the bacteria and/or damage the host (Jett *et al.*, 1994; Fournier and Philpott, 2005; Kuehn and Kesty, 2006). The following is a summary of activities of many bacterial proteins that contribute to host invasion, tissue damage or death.

59. *Collagenase*: Collagenase, produced by *Clostridium histolyticum* and *Clostridium perfringens* (Legat *et al.*, 1994; Rood, 1998), breaks down collagen, the single most abundant protein in mammals. Collagenases are thought to play a major role in the pathology of gas gangrene caused by clostridia because they can destroy the connective tissue barriers.

60. *Spreading Factor*: Hyaluronidase, or more descriptively "spreading factor", affects the physical properties of tissue matrices and intercellular spaces. Hyaluronidase, an enzyme produced by streptococci, staphylococci and clostridia (Bergan, 1984; Li *et al.*, 2000), is also a component of venom from snakes, spiders, jellyfish, etc (Girish *et al.*, 2004; Kuhn-Nentwig, 2004). The enzyme attacks the ground substance of connective tissue by depolymerizing hyaluronic acid thereby promoting the spread of the bacteria.

61. *Kinases*: Streptokinase and staphylokinase are produced by streptococci and staphylococci, respectively. Kinase enzymes convert inactive plasminogen to plasmin which digests fibrin and prevents clotting of the blood. The relative absence of fibrin in bacterial lesions allows more rapid diffusion of the bacteria (Gladysheva, *et al.*, 2003).

62. *Sialidases/Neuraminidase*: Extracellular sialidases or neuraminidases, produced by various pathogens, have the ability to hydrolyse the sialic acid residues located on many mammalian cell membranes (Rood, 1998). The neuraminidase produced by *Mannheimia haemolytica* decreases the viscosity of respiratory mucus thus providing the bacteria with greater access to the cell surface (Zecchinon *et al.*, 2005).

63. *Toxins*⁴: Many toxins act on the animal cell membrane by insertion into the membrane (forming a pore that results in cell lysis), or by enzymatic attack on phospholipids, which destabilises the membrane. They may be referred to as lecithinases or phospholipases, and if they lyse red blood cells they may be called hemolysins. Hemolysins, notably produced by staphylococci (*i.e.*, alpha toxin), streptococci (*i.e.*, streptolysin/pneumolysin) and various clostridia, may be channel-forming membrane toxins capable of damaging a broad range of eukaryotic cell types (Awad *et al.*, 1995; Menzies *et al.*, 2000; Doran *et al.*, 2002). Lecithinases destroy lecithin (phosphatidylcholine) in cell membranes (Awad *et al.*, 1995; Appelberg and Leal, 2000). Phospholipases, for example alpha toxin produced by *Clostridium perfringens*, hydrolyse phospholipids in cell membranes by removal of polar head groups. Leukocidin, a bacterial exotoxin similar to streptolysin, is produced by staphylococci and specifically lyses phagocytes and their granules. Although leukocidin may be referred to as a bi-component leukotoxin (Morinaga *et al.*, 2003;

4. Listings of toxins are provided in Gill (1982, 1987).

Futagawa-Saito *et al.*, 2004), it should not be confused with the leukotoxins of the RTX family described below.

64. Exotoxins have sometimes been categorised according to the cells primarily affected by the toxin. For example, leukotoxins are a group of exotoxins that produce their primary effect on leukocytes, especially polymorphonuclear cells (PMNs). *Mannheimia (Pasteurella) haemolytica*, one of the key pathogens associated with bovine respiratory disease complex produces a leukotoxin (LKT) that both activates and kills bovine leukocytes. Atapattu and Czuprynski (2005) have shown that LKT produced by *Mannheimia haemolytica* induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway. While LKT is able to bind leukocytes from various animal species, it is only cytotoxic for ruminant leukocytes. For evaluators and notifiers, this underlies the importance of ensuring that appropriate test assays have been conducted. This virulence factor is a member of the RTX (repeats in toxins) family of multidomain Gram-negative bacterial toxins. RTX toxins fall into two categories: hemolysins which attack different cell types from a variety of species and leukotoxins which show a marked specificity for both cell type and host species (Lally *et al.*, 1999). Other bacteria that produce RTX toxins include: hemolysins produced by *E. coli*, *Bordetella pertussis*, *Actinobacillus* spp. and leukotoxins produced by *Actinobacillus actinomycetemcomitans* and various *Pasteurella* spp., (Narayanan *et al.*, 2002; Davies *et al.*, 2002; Ward *et al.*, 2002).

65. *Toxins With Short-Range Effects Related to Invasion:* Bacterial protein toxins which have adenylate cyclase activity, are thought to have immediate effects on host cells that promote bacterial invasion. One component of the anthrax toxin (EF or Edema Factor) is an adenylate cyclase that acts on nearby cells to cause increased levels of cyclic AMP and disruption of cell permeability (Leppla *et al.*, 1982). One of the toxin components of *Bordetella pertussis*, pertussis adenylate cyclase, has a similar effect. These toxins may contribute to invasion through their effects on macrophages or lymphocytes in the vicinity which are playing an essential role to contain the infection.

66. To establish an infection, bacteria carefully orchestrate a number of bacterial factors and determinants which have a role in determining pathogenicity. Proficient coordination of these factors is required for bacterial survival and successful colonisation. Thus, bacteria have developed sophisticated regulatory systems to adapt gene expression to changing environmental conditions. Bacterial communication, for instance, plays an important role in regulation of various aspects of bacterial activity, *e.g.* the onset of virulent behaviour, but is not generally taken into account as a virulence factor.

SECTION III: MOLECULAR ASPECTS OF PATHOGENICITY

III.1 Molecular Genetic Definition of Bacterial Virulence

67. The application of molecular biology to microbial pathogenesis was phrased by Falkow (1988) in a molecular form of Koch's postulates: (i) the phenotype or property under investigation should be associated with pathogenic members of a genus or pathogenic strains of a species; (ii) specific inactivation of the gene(s) associated with the suspected virulence trait should lead to a measurable loss in pathogenicity or virulence; and (iii) reversion or allelic replacement of the mutated gene should lead to restoration of pathogenicity. Meeting these postulates requires the technical possibility to directly affect the genes in question, and, even more important, the availability of models to measure virulence. As this is not always feasible, an alternative approach was added: (iv) the induction of specific antibodies to a defined gene product should neutralise pathogenicity. This fourth postulate is sometimes taken alone: when antibodies against a certain factor protect an animal from disease, this is sufficient to call this factor a virulence factor.

68. Like Koch's postulates, the 'molecular Koch's postulates' cannot always be applied rigidly. If the virulence phenotype is multifactorial, as will usually be the case, the gene products identified as virulence factors may either be a 'classical' virulence factor, or an accessory factor that is essential for expression of the phenotype, but not directly involved in it. As an example: the fimbriae, hair like surface structures, that are virulence factors of uropathogenic *Escherichia coli* strains carry an adhesin molecule at their tip that performs the directly virulence related task of adherence to epithelial cells of the host. They can however only efficiently perform this task when carried at the tip of the fimbriae that are composed of other protein molecules that lack the adhesive property. The gene identified as a virulence factor may not even be a structural gene, coding for a gene product, but may have a regulatory function in the expression of the structural gene. In the literature there is a tendency to describe all genes that pass the tests described in the molecular Koch's postulates as virulence genes. This approach has resulted in the identification as 'virulence genes', of genes that are not directly involved in virulence as such, but are indispensable for the expression of the virulent phenotype because they are required in some way for correct expression of virulence genes. In fact, the molecular approach may detect a whole spectrum of 'virulence genes' ranging from 'true' virulence genes to genes encoding 'house-keeping enzymes' that through some remote mechanism influence the virulence phenotype. This may indicate a need for a more restrictive definition of virulence genes than simply genes that are detected in virulence assays.

69. A definition of bacterial virulence should enable the discrimination between 'true' virulence genes that are directly associated with the virulent phenotype, and accessory genes, that will also be identified as virulence genes by screening methodologies that rely on gene inactivation resulting in attenuation of virulence. A well-known example of a housekeeping gene identified as a virulence factor is the gene *aroA* (as well as other 'housekeeping' genes, see Uzzau *et al.*, 2005), inactivation of which results in attenuation of pathogenicity. The *aroA* gene, however, is involved in aromatic amino acid biosynthesis, and as such is present in both pathogens and non-pathogens and not considered a virulence gene. This is easily understood in the case of *aroA*, but when the gene product has no known housekeeping function, such genes would be described in the literature as virulence genes. The problem is where to draw the line in the continuum between 'virulence-associated genes', and 'housekeeping genes'. In order to exclude

housekeeping genes from the set of 'virulence' genes, the requisite is often added to Falkow's molecular postulates that virulence genes should not be expressed outside the host. However, this would exclude certain well-characterised virulence genes, for instance lipopolysaccharide (LPS)-producing enzymes are expressed under all circumstances, and yet LPS is a generally accepted virulence factor. Moreover, lack of expression outside the host may be a reflection of the applied culture conditions. In conclusion, the border between virulence-associated genes and housekeeping genes cannot be sharply defined.

1) Molecular approaches to identify virulence genes

70. Three basic approaches are used to identify virulence genes: genetic methods to obtain phenotypic evidence for virulence, methods based on the proposed immunogenicity of virulence factors for immunological evidence, and comparative genetic methods that yield additional indirect evidence.

71. *Phenotypic evidence.* Within the genetic methods two approaches are used: (i) inactivation of a virulence gene must result in loss of virulence; or (ii) complementation of a virulence gene to a non-virulent strain must add virulent properties. It should be noted that both principles are heavily dependent on models to determine the virulent phenotype. Models to determine virulence are ideally animal models that minutely mimic natural disease, but these are not always available. More often animal models have to be used that display only some of the naturally occurring characteristics, or in vitro models that only poorly resemble disease characteristics. Most processes leading to virulence are multi-factorial. The complicated interaction of host and bacteria is often ignored when in vitro models are applied. Even under simplified conditions of in vitro models a presumably straightforward process such as bacterial invasion can be driven and regulated by multiple genes and gene loci, which work in concert or complementarily. Inactivation of one link of the chain may eliminate invasiveness, but complementation in a different setting may require several genetic loci. Alternatively, inactivation of a factor may be overcome by alternative factors so that loss of virulence is not observed, but complementation in a different environment may have strong phenotypic effects. The relevance of the applied models to extrapolate their outcome as phenotypic evidence of virulence is a point of debate, which is pragmatically ignored by lack of alternatives.

72. *Immunological evidence.* A second approach for identifying virulence genes is based on the proposed immunogenicity of virulence factors. Knowing that acquired immunity can protect against disease, it is assumed that protective antibodies are directed against virulence-associated genes. When an infection results in an antigenic response directed against one or more specific antigens, this is taken as a strong indication that these antigens represent virulence-associated factors.

73. *Comparative genetical evidence* Examples of the genetic approach to identification of potential virulence-associated genes are the identification of (i) genes with significant homology to known virulence-associated genes; (ii) related genes that show variation that can be interpreted as antigenic variation; (iii) genes that are shown to be present in (more) virulent strains, while absent in avirulent strains. Comparative genetic approaches are further discussed in section II.1.2, on trends in virulence gene identification.

74. In addition to these approaches, several techniques have been developed to identify and characterise bacterial genes that are induced during the intracellular infection and therefore, potentially, may play a role in pathogenesis. Examples are the search for genes that are specifically induced in the host, and 'signature-tagged mutagenesis', involving comparative hybridisation to isolate mutants unable to survive the environmental conditions in the host (Mahan *et al.*, 1993; Chiang *et al.*, 1999; and Harb and Abu Kwaik, 1999). A very powerful approach to isolate mutants that may be affected in a virulence gene is signature tagged mutagenesis (STM) as discussed by Autret and Charbit (2005). The general technique of STM can be applied to find specific genes involved in survival persistence of a bacterium in a host; virulence genes would fall into this class of genes (Wassenaar and Gastra, 2001). The only prerequisite

for a gene to be found by STM is that its loss of function should not result in a lethal phenotype under conditions of growth *in vitro*, in broth. This is probably not an impediment for most virulence genes to be identified by this technique. The STM approach involves transposon (usually) mutagenesis of a bacterial strain, followed by pooling of a number of mutants that can be individually recognised by a polymerase chain reaction (PCR) amplifiable tag. The pooled mutants are inoculated in an animal model, and bacteria retrieved from the animal are analysed for mutants that are present, as shown by the presence of their tag. Mutants that are lost have a function in the pathogenic process, or at least a function is needed to survive and be retrieved in the experiment.

75. Ideally, for the identification of virulence, several approaches should lead to the same gene or set of genes, and the characterisation of a gene as virulence-associated should be based on evidence from more than one approach. Even then, the controversy between housekeeping genes and virulence genes is not always solved. For example, the housekeeping magnesium transport system of *Salmonella typhimurium*, *mgtA/B*, is under *PhoP/PhoQ* regulation, and is activated during invasion *in vitro* (Smith and Maguire, 1998). One example is glutamine synthetase of *Salmonella typhimurium*, which is under the regulation of *ntrC* (an alternative sigma factor that can be indicative for *in vivo* regulation of expression) and which was identified as a virulence gene based on phenotypic evidence, since inactivation resulted in attenuation (Klose and Mekalanos, 1997). The enzyme presumably provides glutamine to the organism while surviving in the host, and could for that reason be considered a virulence-associated gene that enables colonisation. Since glutamine synthetase is also present in apathogenic bacteria it is not considered a virulence gene in the comparative genetic approach. As the absence of virulence genes in apathogenic bacteria receives a lot of weight in this approach, two points need to be considered: 1) the outcome of such comparative genetics is heavily dependent on the content of the databases used; and 2) gene function is not always correctly predicted by comparative genetics alone. Putative virulence gene candidates identified in this way should therefore at least be confirmed by phenotypic evidence, despite the mentioned shortcomings of such evidence.

2) Trends in virulence gene identification

76. Due to the the explosive developments in genomics it is now feasible to analyse the complete genome of bacterial pathogens by *in silico* subtractive hybridisation. With the expanding annotation of genes from genome sequences, this can lead to the identification of new virulence genes (Field *et al.*, 1999; Frosch *et al.*, 1998). The annotation of these newly sequenced genes is based on sequence identity. This identification of virulence genes by comparative genomics, based on genetic similarity is, however, risky for several reasons.

77. An acceptable level of sequence conservation is seen as (indirect) evidence of conserved function, so that the gene function of a newly sequenced gene is extrapolated from a well-characterised analogue in another species. However, genes may have a niche-adapted function in a particular organism, and this may have its effect on the role of the gene product in virulence. Functional domains may not be conserved (Lee and Klevit, 2000). Therefore, sequence homology does not always predict function, and even when there is a high degree of genetic conservation between a non characterized gene and a known virulence gene, the function of the gene product of the non characterized gene as a virulence factor should first be experimentally tested before functional homology is assigned. Until then, the newly identified virulence gene should be annotated as 'putative'. Mis-annotation based on 'putativism' is quite common, since it is now easier to generate sequencing data than to experimentally prove a function of the given gene product.

78. Another, diametrically opposed, pitfall of comparative genetics is that genes that share no sequence homology can have identical functions, as is demonstrated for *actA* of *Listeria monocytogenes*

and *IcsA* in *Shigella flexneri* whose gene products recruit host cell actin (Strauss and Falkow, 1997). This type of functional similarity will go unnoticed by genome comparison.

79. Many virulence genes display antigenic polymorphisms, presumably to evade the selection pressure of the host immune system (Deitsch *et al.*, 1997). The correlation between polymorphism and virulence is so strong that polymorphisms observed *in silicio* are taken as indirect evidence for a role in virulence. It should be noted that the term polymorphism is used for different phenomena. The term is used when one isolate of a bacterial species can produce antigenic variants of a gene product by means of gene multiplication, alternative expression, or post-translational modification. 'Polymorphism' is also used for antigenic or genetic differences observed between isolates of the same species, for which the term 'allelic polymorphism' is more exact. In addition, slippage during replication or translation can cause variation in the number of DNA repeats (with units of 1 to 7 nucleotides) present within a gene, leading to polymorphic offspring (either represented in DNA or in protein) of a given cell (Van Belkum *et al.*, 1998). All of these polymorphic mechanisms serve the general goal of adaptation to varying conditions. In the case of pathogens this is often, though not exclusively, a mechanism to avoid host defense responses. With the high throughput of sequencing data, it becomes possible to identify putative virulence properties for genes based on the polymorphic nature of their predicted translation products.

80. In conclusion, different paths lead to the identification of virulence genes. A 'top down' approach, starting from a single pathogen, will start by defining the pathogenic phenotype of the organism ('adhering', 'invasive', 'toxin producing', 'phagocytic survival'), and subsequently zoom in on the virulence genes responsible for this phenotype. A 'bottom up' approach will start from an annotated genome sequence, from which putative virulence genes can be identified by comparative genetics. The relevance of such identified putative virulence genes for the pathogenic phenotype then remains to be proven. For this a 'lateral' approach can be useful, as pathogens often employ similar pathogenic mechanisms, and analogies between virulence factors can be used for identification strategies. In parallel, genetically related organisms that have a different pathogenic repertoire can be compared to identify the genes responsible for the differences in virulence. Section III presents an overview of genes that are involved in different stages of pathogenicity: host recognition and adherence, host invasion, multiplication in the host, the ability to overcome the host immune response and host defense systems and the ability to damage or kill the host.

3) The perspective of virulence genes correc

81. Understanding of bacterial virulence factors can be biased because of the experimental setup applied to identify or study the factor (Quinn *et al.*, 1997). For instance, many bacterial toxins are described as 'haemolysin', because they have been originally recognised as cytolytic to erythrocytes. However, in real life these toxins may not be targeted at erythrocytes, but at leukocytes or other host cells instead. This distinction may seem irrelevant, however, the classical role of haemolysins is thought to be release of heme as an iron source, and as such the term haemolysin (and the haemolytic assay) is often erroneous and can be problematic with respect to our understanding of an organism's pathogenicity. This is just one example of how the perception of bacterial virulence factors is influenced by experimental design.

82. Pathogenicity and virulence are often addressed in an anthropomorphic manner, *i.e.* the incorrect concept that it is the 'aim' of pathogenic bacteria to cause disease in their host. Like every organism, pathogens have adapted to occupy their ecological niche. Their close association with a host causes damage to their host. Often this damage is 'coincidental', but it may even be beneficial to the survival or spreading of the pathogen. Examples are the release of nutrients by cell damage, or enabling contagion of the next host by inducing coughing or diarrhoea. The degree of damage is dependent on the equilibrium that results from the interplay of pathogen and host, and may, for instance, be dependent on the immune response of the individual (Casadevall and Pirofski, 1999). The conditions that result in disease can vary among host individuals, and from host species to host species. This adds to the difficulties to identify the

bacterial genes that are directly responsible for the disease. Ideally, experimental shortcomings, subjective observations, and the anthropomorphic view on pathogenicity should all be considered when establishing the relevance of a certain virulence gene to the pathogenicity of a micro-organism.

4) Classification of virulence genes

83. From the previous sections it will be clear that there are many ways of defining, identifying, and testing virulence genes. But, since each pathogen has evolved to fit its own niche, different pathogens do not necessarily share common pathogenic characteristics. Despite the recognition of common themes in bacterial virulence (Finlay and Falkow, 1989; Finlay and Falkow, 1997), a larger part of all virulence genes described in the literature that resulted from over 30 years of research have little in common, other than having some function in virulence. In order to interpret the vast amount of data on this subject these genes need to be classified.

84. Regulators need a good understanding of the significance of a given virulence gene in its physiological background. For performing a regulatory review of the role of a donor gene as a virulence factor in the physiological background of the recipient micro-organism, information should be available on the role of the donor gene as a virulence factor in the donor micro-organism, and on the lifestyle of the recipient micro-organism. As noted above, a large number of interacting factors affect the ability of a micro-organism to lead a pathogenic lifestyle, and acquisition of a single gene in the absence of other genes necessary to the pathogenic lifestyle will not likely convert a non-pathogen to a pathogen. Only if the newly acquired gene can have a role in the pathogenic life style of the recipient micro-organism can an interaction be expected between the newly acquired gene and the resident genes contributing to the pathogenic lifestyle. Wassenaar and Gaastra (2001) have proposed a classification of virulence genes according to their potential role in pathogenic lifestyles that should be helpful to evaluate the potential influence of newly acquired genes on virulence.

85. Wassenaar and Gaastra (2001) discriminate among four lifestyles: exclusive pathogens, host dependent pathogens, opportunistic pathogens and fully non-pathogenic organisms. Seven types of virulence gene classes are distinguished: true virulence genes, directly involved in interactions with the host and responsible for pathological damage (*e.g.*, toxins); colonisation genes, determining the localisation of the infection; host defense system evasion genes (*e.g.*, immunoglobulin specific proteases); processing genes involved in the biosynthesis of virulence life style factors (*e.g.*, chaperonins; gene products with a virulence life style substrate), secretory genes, virulence housekeeping genes (*e.g.*, urease, catalase), and regulatory genes, involved in the regulation of virulence life-style genes. Further subclasses may be identified for these classes.

III.2 Evolution and Spread of Virulence Genes; Pathogenicity Islands

86. In general, three mechanisms can be proposed for the evolution of pathogens: acquirement of virulence genes from existing pathogens by horizontal gene transfer; a change in host specificity (host jump) of an existing pathogen, possibly together with, or as a result of, the acquirement of genes to adapt to a new ecological niche; and evolution of new virulence genes from the existing gene pool of a bacterial species, resulting in (an increase of) virulence.

87. Over the past few years it has become apparent that of these, the evolutionary consequences of horizontal gene transfer are probably the most drastic. There is ample evidence that virulence genes have spread by horizontal gene transfer, by all processes known to contribute to the process (see the OECD guidance document on horizontal gene transfer between bacteria).

88. In the late 1980s Hacker and colleagues (Dobrindt *et al.*, 2004, see also Schmidt and Hensel, 2004) were the first to notice that pathogenicity related genes are often located on mobile genetic elements, called 'pathogenicity islands' (PAIs). PAIs may be identified as strain specific sequences by subtractive hybridisation between virulent and avirulent strains of the same species. They are frequently found integrated in or near to tRNA genes, which are perfect properties for docking sites because they are highly conserved and often present in multiple copies. They are characterised by (the remains of) insertion sequences (IS) at their borders that, if still functional, may lead to genetic instability and to spread of the PAI to other strains by horizontal gene transfer. The GC content and codon usage of PAIs is often different from the GC content and codon usage of the rest of the genome, which is taken as an indication of their recent acquisition in the genome.

89. PAIs typically contain sequences that code for gene products that have a (putative) role in virulence. The uropathogenic strain 536 of *E. coli* that has been extensively studied by the group of Hacker (Brzuszkiewicz *et al.*, 2006), provides a good example of what might be found on PAIs. *E. coli* 536 contains seven PAIs coding for different types of fimbriae, haemolysins, a capsule, a siderophore system, a Yersiniabactin, proteins involved in intracellular multiplication, and for a hybrid peptide-polyketide genotoxin that causes cell cycle arrest and eventually cell death of eukaryotic cells that are in contact with this *E. coli* strain (Nougayrède *et al.*, 2006).

90. The ongoing elucidation and analysis of prokaryotic genomes has shown that not only pathogenicity related traits are located on 'islands'. PAIs are a specific example of a 'genomic island' (GEI), the term that has been coined for the phenomenon that bacteria carry in their genome a flexible gene pool that encodes additional traits that can be beneficial under certain circumstances, and that allows them to adapt to a specific niche, while the more constant part of the genome takes care of 'household' functions. GEIs are commonly found in the 'metagenome', *i.e.* the combined genomes, of bacteria that share a niche. They would appear to facilitate exchange of useful genes between these bacteria that are mutually supportive in occupying the same environment. The traditional view of bacterial evolution occurring through clonal divergence and selection must be broadened to include gene exchange as a major driving force for adaptation to specific niches. PAIs would be an example of this phenomenon of gene transfer, in facilitating bacteria to occupy the niche of pathogenic organisms.

91. The genome flexibility that leads to enhanced virulence is not restricted to acquisition of virulence factors; it may also include loss of genomic sequences, as has been shown for *Shigella flexneri* and enteroinvasive *E. coli* (Maurelli *et al.*, 1998). In general, it appears to be evolutionarily profitable to counteract the acquisition of genes that provide selective advantage with loss of genetic information that can be dispensed with in the new niche, as is the case for instance for intracellular symbionts.

92. In conclusion pathogenicity is not a singular trait of a singular type of organisms, 'the pathogens'. Rather, pathogenic traits are adaptive traits that equip a bacterium for a specific lifestyle in a specific niche that happens to be the surface or interior of the body.

SECTION IV: ASSESSING POTENTIAL BACTERIA-MEDIATED ADVERSE HUMAN HEALTH EFFECTS

93. In the previous sections it has been argued that deleterious effects that are caused by pathogenic organisms can be understood as effects of a 'life style' that enables these organisms to colonize and use specific environments in the human or, in general, animal body as a niche. This line of thinking has been broadened by Casadevall (2006), who has pointed out that many micro-organisms in the environment have developed lifestyles that allow them to interact with the other organisms that they encounter in the environment. The same or similar gene products may have a role in different lifestyles, *e.g.* the interaction with fungi, protozoa as well as vertebrates. Bacterial strains that have no directly apparent role in human pathogenicity, for instance because they do not survive or replicate at 37^o C, may therefore still carry genes that code for gene products with a potential role as virulence factors in bacteria that are more compatible with a lifestyle as human pathogen. This complicates the risk analysis of deliberate release of environmental strains, particularly if these strains have been subject to genetic modification.

IV.1 Risk assessment of environmental release of bacterial strains that may cause adverse human health effects

94. Environmental release of bacteria should be preceded by a risk assessment. One aspect that has to be taken into account in this risk assessment are the potential adverse human health effects of the bacterial strain that is released. In environmental risk assessment, the risk is expressed as the magnitude of the potential hazard, in this case the degree of human pathogenicity of the bacterial strain, combined with the likelihood that the hazard actually occurs, *i.e.*, the likelihood that human exposure to the bacteria will occur under the conditions of the release in such a way that human pathogenic effects may occur. The WHO Laboratory Safety Manual (WHO, 2004⁵, chapters 2 and 16) provides helpful considerations on the risk assessment of (potentially) pathogenic organisms. These considerations apply primarily to laboratory settings, but they can be easily adapted and applied to environmental settings.

95. The risk group (see section I.2) of the bacterial species is a first approximation of the degree of pathogenicity. But assessing the degree of pathogenicity of a bacterial strain calls for a clear identification of the location of the strain in the spectrum from clear non-pathogen to clear pathogen. This should be done with a lot of caution. Truly apathogenic bacteria will lack any ability to survive in a human host, or cause any adverse effects. Bacteria that are incompatible with the human niche, *e.g.*, bacteria that cannot survive at temperatures between 30-42^o C, or that are exclusively phototrophic or lithotrophic would be expected to be apathogenic. Still, one should be careful drawing this conclusion. For instance, lithotrophic bacteria have been found in infections associated with surgical implants in the human body (Dempsey et al., 2007). Indeed, Casadevall (2006) has pointed out that bacterial strains that have lifestyles that do not link them to human pathogenicity can carry genes that code for gene products with a potential role as virulence factors in bacteria that are or could develop into human pathogens. Falkow (2008) argues that it is difficult to separate the pathogenic from the commensal lifestyle. What is the Difference Between a pathogen and a commensal? Pathogens possess the *inherent* ability to cross anatomic barriers or breach other host defenses that limit the survival or replication of other microbes and commensals. Therefore, most pathogens establish themselves in a niche usually devoid of other stable microbial populations. These invasive

⁵ Available at <http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf>

properties are essential for their survival in nature, and, are often host specific. However, many “commensal” bacteria can cause disease, *e.g.*, Group A and B streptococci, *S. pneumonia*, *H. influenza*). Many features that are seen as virulence factors of pathogens (pili, antiphagocytic proteins, capsules) are common in non-pathogens. Virulence factors may simply be examples of “adaptive factors” common to all bacteria.

96. Bacterial strains that have been derived from wild type isolates from the environment may have changed significantly in their pathogenicity compared to fresh wild type isolates. This may in particular be the case if the strain have been mutated, *e.g.*, for attenuation, or if new virulence related genes have been introduced by genetic modification. But also the fact that strains have been handled in the laboratory during many generations, may have led to the occurrence of mutants with changed properties. Loss of properties that have no function in survival under laboratory conditions, like virulence factors, occur quite frequently under these circumstances. As in all cases of attenuation, strains that have been attenuated in this way should be thoroughly tested for stability of the non-pathogenic phenotype (see also paragraph 11).

97. Predicting the effects of introduced virulence genes is not straightforward. If ‘true virulence genes’ (as defined in section III) have been introduced, an effect on pathogenicity is more likely, as these genes are directly responsible for pathological damage, such as toxins. However, the degree of damage that these gene products can cause is highly dependent on the context of the pathogenic ‘lifestyle’ of the bacterium, which depends on the secondary virulence factors available in the bacterial strain. This discussion is especially pertinent for medical and veterinary applications of potentially (a)pathogenic strains. The discussion is also highly relevant for risk assessments of releases of environmental strains that have been modified in the laboratory. The case of the *Burkholderia cepacia* complex (Bcc) has already been mentioned as an example (see paragraph 8). The species in this complex have have for a long time be seen as (potential) plant pathogens, and their potential as human (opportunistic) pathogens has only recently been recognized. It would require more insight in the lifestyle of these bacteria to be able to predict the role of introduced virulence genes in the establishment of pathogenic potential. In cases like this, caution should be used in establishing conclusions on their pathogenicity.

98. The likelihood of the strain actually causing adverse human health effects will depend on the exposure of humans to the bacterial strain during and after the release. Adverse effects are only to be expected if the exposure is such that it will lead to contact of humans with the bacteria in sufficient numbers and in such a way that pathogenic effect may ensue, *e.g.*, by ingestion, inhalation, dermal contact. Factors that determine the degree of exposure are: a) the number of bacteria released into the environment, b) spread during release, dependent on the method used, *e.g.*, by aerosols, injection or mixing in the soil, seed coating, c) survival, and d) dissemination after release, *e.g.*, through surface and subsurface water movement, by soil fauna, or by disturbance of the site of application. Spreading of aerosols is dependent on conditions of wind at the time of the application; survival of bacteria in aerosol droplets is dependent on environmental factors, *e.g.*, humidity and UV radiation. Survival of bacteria in soil is variable for different strains of the same species. In many cases where bacteria have been introduced into the environment a rapid decrease has been observed, *i.e.*, the number of detectable bacteria drop below the detection limit⁶ of a direct viable count within months or even weeks. This is even the case for many strains that are well-adapted to a soil-lifestyle, *e.g.*, the root colonising *Pseudomonas fluorescens*. The bacteria are however not ‘lost’ from the environment, and may appear again readily if environmental circumstances are favourable, for instance if the plant who’s they are prone to colonize is present again in the environment.

⁶ For guidance on the detection of bacteria in soil, see the Guidance document on methods for detection of micro-organisms introduced into the environment: bacteria (ENV/JM/MONO(2004)7), <http://www.rebeca-net.de/downloads/oecd%20guid%20doc%20detection%20of%20micro-organisms.pdf>

99. If a human health hazard is expected safety measures should be taken in the first place to protect persons present during release. Safety measures to reduce effects of the bacteria after application should be based on worst case assumptions on survival and spreading. They may be reduced if the results of monitoring show a reduction of survival and spreading.

IV.2 General considerations for assessing changed pathogenicity of parental micro-organisms as a result of genetic modification

100. The risk assessment of genetically modified micro-organisms requires careful consideration of numerous factors, not the least of which is the genetic composition of both the recipient and the donor organisms, and their respective lifestyles and phenotypic expression. While the intended use of the organism is factored into the initial assessment, some foresight should be given to potential unintended uses, in particular if the genetically modified strains are meant to be commercially available.

101. Genetic modification may cause changes in the various factors that enable a bacterium to reach a particular niche, colonize and perhaps disseminate from that niche, even if such a change was not the objective of the modification. As described in the previous sections, pathogenicity is the capacity to cause disease, and is related to the ability of a micro-organism to reach, occupy, and adapt to a particular niche and to subsequently cause harm. Thus, when performing an assessment of potential human pathogenicity, one should consider how the modification may change a bacterium's capacity to cause disease.

102. There are several determinants that should be considered when assessing bacterial pathogenicity as a result of genetic modification. Consideration should be given to the biological and ecological characteristics of the parental strain, *i.e.* its 'lifestyle', in as far as it is compatible with causing human pathogenicity. Due to the lifestyle of a vast majority of bacteria in the environment, *e.g.*, psychrophilic or thermophilic, lithotrophic or phototrophic bacteria, it is not likely that they will turn into potential human pathogens just by the introduction of one virulence factor derived from a human pathogenic strain. On the other hand, genes derived from bacteria that are not suspected human pathogens on basis of their lifestyle may still code for gene products that can contribute to virulence.

103. Modifications may involve genes whose products are not inherently harmful but adverse effects may still arise from the modification or exacerbation of existing traits. This may arise as the result of the product of an inserted gene acting alongside existing pathogenic determinants. Alternatively it is possible that modification of normal genes may also alter pathogenicity. In an assessment, the following points should be considered:

- Characteristics of the recipient, for instance whether the recipient is a recognised pathogen.
- Existing traits in the recipient organism that might lead to an increase in pathogenicity or infectivity when altered (*e.g.*, alteration of host range or tissue tropism).
- The likelihood that any disabling mutation within the recipient might be overcome, for example through complementation or reversion, due to the insertion of the foreign gene.
- Whether the foreign gene encodes a pathogenicity determinant from a related organism (toxin, invasin, integrin, and surface structures such as fimbriae, LPS and capsule).
- When the foreign DNA does include a virulence factor, the feasibility that this gene could contribute to the pathogenicity of the genetically modified micro-organism, or whether the virulence factor provides resistance to host defense mechanisms.

- Whether susceptibility to antibiotics or other forms of therapy may be affected as a consequence of the genetic modification.
- Whether attenuated or inactivated strains truly are avirulent.
- Whether a surface component that might bind to a different receptor than that used by recipient micro-organism could increase virulence.
- Whether genes with other adverse effects (*e.g.*, oncogenes, growth hormones) are present.
- Genes encoding toxins, and other gene products that cause pathogenic effects even in the absence of live organisms require careful consideration.
- When mutations are introduced that inactivate specific virulence factors of recognised pathogens, whether the stability of the mutation has been demonstrated, and whether attenuation has been shown to be sufficient so that the resulting strain can be considered apathogenic.
- When the insert encodes a protein that does not interact with the pathogenic properties of the parental strain but may cause pathogenic reaction, *e.g.*, an oncogenic protein, or a modulator of growth (hormone, cytokine) or other endocrine factors, or in general, any other protein with a potentially harmful biological activity.

The point to be considered summed up in this paragraph will not be exhaustive. One reason for this is that little experience exists with the risk assessment of deliberate release of genetically modified bacterial strains. When more experience is available, this paragraph should be reviewed.

SECTION V: REFERENCES

- Aebi, C., E.R. Lafontaine, L.D. Cope, J.L. Latimer, S.L. Lumbley, G.H. McCracken Jr, and E.J. Hansen. 1998. Phenotypic effect of isogenic *uspA1* and *uspA2* mutations on *Moraxella catarrhalis* 035E. *Infect Immun.* 66(7):3113-9.
- Alonso, A. and F. Garcia-del Portillo. 2004. Hijacking of eukaryotic functions by intracellular bacterial pathogens. *Int Microbiol.* 7(3):181-91.
- Al-Shangiti, A.M., C.E. Naylor, S.P. Nair, D.C. Briggs, B. Henderson and B.M.Chain. 2004. Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. *Infect Immun.* 72(7):4261-70.
- An, Y.H., R.B. Dickinson and R.J. Doyle. 2000. Mechanisms of bacterial adhesion and pathogenesis of implant and tissue infections. *In: Handbook of Bacterial Adhesion: Principles, Methods and Applications.* Y.H. An and R.J. Friedman (eds.). Humana Press Inc. Totowa, NJ.
- Appelberg, R. and I.S. Leal. 2000. Mutants of *Listeria monocytogenes* defective in *In vitro* invasion and cell-to-cell spreading still invade and proliferate in hepatocytes of neutropenic mice. *Infect Immun.* 68(2):912-4.
- Aristoteli, L.P. and M.D. Willcox. 2003. Mucin degradation mechanisms by distinct *Pseudomonas aeruginosa* isolates *in vitro*. *Infect Immun.* 71(10):5565-75.
- Armant, M.A. and M.J. Fenton. 2002. Toll-like receptors: a family of pattern-recognition receptors in mammals. *Genome Biol.* 3:3011.1-3011.6
- Atapattu, D.N. and C.J. Czuprynski 2005. *Mannheimia haemolytica* leukotoxin induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway. *Infect Immun.* 73(9):5504-13.
- Athamna, A, M.R. Kramer and I. Kahane. 1996. Adherence of *Mycoplasma pneumoniae* to human alveolar macrophages. *FEMS Immunol Med Microbiol* 15:135-41.
- Autret, A. and A. Charbit. 2005. Lessons from signature-tagged mutagenesis on the infectious mechanisms of pathogenic bacteria. *FEMS Microbiol. Rev.* 29, 703–717
- Awad, M.M., A.E. Bryant, D.L. Stevens and J.I. Rood. 1995. Virulence studies on chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of alpha-toxin in *Clostridium perfringens* -mediated gas gangrene. *Mol Microbiol.* 15(2):191-202.
- Azghani, AO, S. Idell, M. Bains and R.E. Hancock. 2002. *Pseudomonas aeruginosa* outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. *Microb Pathog.* 33:109-14.

- Balish, M.F., S.M. Ross, M. Fisseha and D.C. Krause. 2003. Deletion analysis identifies key functional domains of the cytoadherence-associated protein HMW2 of *Mycoplasma pneumoniae*. *Mol Microbiol* 50:1507-1516.
- Barenkamp, S.J. and J.W. St. Geme III. 1996. Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable *Haemophilus influenzae*. *Mol Microbiol*. 19(6):1215-23.
- Bassinat, L., P. Gueirard, B. Maitre, B. Housset, P. Gounon and N. Guiso. 2000. Role of adhesins and toxins in invasion of human tracheal epithelial cells by *Bordetella pertussis*. *Infect Immun*. 68(4):1934-41.
- Bassler, B.L., R. Losick. 2006. Bacterially speaking. *Cell* 125:237-246
- Bäumler, A.J., R.M. Tsois and F. Heffron. 1997. Fimbrial adhesins of *Salmonella typhimurium*. Role in bacterial interactions with epithelial cells. *Adv Exp Med Biol* 412:149-58.
- Belkum, A. van, S. Scherer, L. van Alphen and H. Verbrugh. 1998. Short sequence DNA repeats in prokaryotic genomes. *Microbiol Mol Biol Rev*. 62:275-93
- Benz, I and M.A. Schmidt. 1989. Cloning and expression of an adhesin (AIDA-I) involved in diffuse adherence of enteropathogenic *Escherichia coli*. *Infect Immun*. 57(5):1506-11.
- Bergan, T. 1984. Pathogenicity of anaerobic bacteria. *Scand J Gastroenterol Suppl*. 91:1-11.
- Blancou, J., B.B. Chomel, A. Belotto and F.X. Meslin, 2005, Emerging or re-emerging bacterial zoonoses: factors of emergence, surveillance and control. *Vet. Res*. 36:507-22.
- Bonacorsi, S.P., O. Clermont, C. Tinsley, I. Le Gall, J.C. Beaudoin, J. Elion, X. Nassif and E. Bingen. 2000. Identification of regions of the *Escherichia coli* chromosome specific for neonatal meningitis-associated strains. *Infect Immun* 68(4):2096-2101.
- Bonci, A., A. Chiesurin, P. Muscas and G.M. Rossolini. 1997. Relatedness and phylogeny within the family of periplasmic chaperones involved in the assembly of pili or capsule-like structures of gram-negative bacteria. *J Mol Evol*. 44(3):299-309.
- Borriello S.P.. 1998. Pathogenesis of *Clostridium difficile* infection. *J Antimicrob Chemother*. 41 Suppl C:13-9.
- Boyle, E.C. and B.B. Finlay. 2003. Bacterial pathogenesis: exploiting cellular adherence. *Curr Opin Cell Biol* 15:633-639.
- Braun, L., B. Ghebrehiwet and P. Cossart. 2000. gC1q-R/p32, a C1q-binding protein, is a receptor for the InlB invasion protein of *Listeria monocytogenes*. *EMBO J* 19:1458-1466.
- Brinton, C.C. Jr., 1959. Non-flagellar appendages of bacteria. *Nature* 183: 782-786.
- Brophy, P.J. 2002. Subversion of Schwann cells and the leper's bell. *Science* 296:862-863.
- Brzuszkiewicz, E., H. Brüggemann, H. Liesegang, M. Emmerth, T. Ölschläger, Gábor Nagy, K. Albermann, C. Wagner, C. Buchrieser, L. Emödy, G. Gottschalk, J. Hacker, U. Dobrindt. 2006. How to become a uropathogen: Comparative genomic analysis of extraintestinal pathogenic *Escherichia coli* strains. *Proc. Nat. Acad. Sci. USA* 103: 12879-84

- Burdock, G.A. and I.G. Carabin. (2004). Generally recognized as safe (GRAS): history and description. *Toxicology* 1:3-18.
- Cameron, C.E. 2003. Identification of a *Treponema pallidum* laminin-binding protein. *Infect Immun.* 71(5):2525-33.
- Casadevall, A. 2006. Cards of Virulence and the Global Virulome for Humans. *Microbe* 1:359-364
- Casadevall, A. and L-A. Pirofski. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infect Immun.* 67:3703-13
- Casadevall, A. and L-A. Pirofski. 2000. Host-pathogen interactions: basic concepts of microbial commensalisms, colonization, infection and disease. *Infect Immun.* 68:6511-8
- Casadevall, A. and L-A. Pirofski. 2001. Host-pathogen interactions: the attributes of virulence. *J Infect Dis.* 184:337-44
- Chiang, S.L., J.J. Mekalanos and D.W. Holden. 1999. In vivo genetic analysis of bacterial virulence. *Annu Rev Microbiol.* 53:129-54
- Cirillo, S.L., L.E. Bermudez, S.H. El-Etr, G.E. Duhamel and J.D. Cirillo. 2001. *Legionella pneumophila* entry gene *rtxA* is involved in virulence. *Infect Immun* 69:508-17.
- Cockran, R., R. Anderson and C. Feldman. 2002. The role of pneumolysin in the pathogenesis of *Streptococcus pneumoniae* infection. *Curr Opin Infect Dis.* 15(3):235-9.
- Connell, H., M. Hedlund, W. Agace and C. Svanborg. 1997. Bacterial attachment to uro-epithelial cells: mechanisms and consequences. *Adv Dent Res* 11:50-58.
- Conner, C.P., D.M. Heithoff, S.M. Julio, R.S. Sinsheimer, and M.J. Mahan. 1998. Differential patterns of acquired virulence genes distinguish *Salmonella* strains. *Proc Natl Acad Sci U S A.* 95(8):4641-5.
- Cossart, P. and P.J. Sansonetti. 2004. Bacterial invasion: the paradigms of enteroinvasive pathogens. *Science.* 304(5668):242-8. Review.
- Craig, L., M.E. Pique and J.A. Tainer. 2004. Type IV pilus structure and bacterial pathogenicity. *Nat Rev Microbiol* 2:363-378
- Crocquet-Valdes, P.A., K. Weiss and D.H. Walker. 1994. Sequence analysis of the 190-kDa antigen-encoding gene of *Rickettsia conorii* (Malish 7 strain). *Gene.* 140(1):115-9.
- Cue, D., S.O. Southern, P.J. Southern, J. Prabhakar, W. Lorelli, J.M. Smallheer, S.A. Mousa and P.P. Cleary. 2000. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of *Streptococcus pyogenes* by blocking formation of integrin $\alpha 5 \beta 1$ -fibronectin-M1 protein complexes. *Proc Natl Acad Sci U S A.* 97(6):2858-63.
- Cummings, C.A., M.M. Brinig, P.W. Lepp, S. van de Pas and D.A. Relman. 2004. *Bordetella* species are distinguished by patterns of substantial gene loss and host adaptation. *J Bacteriol.* 186(5):1484-92.
- Davies, R.L., S. Campbell and T.S. Whittam. 2002. Mosaic structure and molecular evolution of the leukotoxin operon (lktCABD) in *Mannheimia (Pasteurella) haemolytica*, *Mannheimia glucosida*, and *Pasteurella trehalosi*. *J Bacteriol.* 184(1):266-7.

- Dempsey, K.E., M.P. Riggio, A. Lennon, V.E. Hannah, G. Ramage, D. Allan and J. Bagg. 2007. Identification of bacteria on the surface of clinically infected and non-infected prosthetic hip joints removed during revision arthroplasties by 16S rRNA gene sequencing and by microbiological culture. *Arthritis Research & Therapy* 9:R46.
- de Repentigny, L., F. Aumont, K. Bernard and P. Belhumeur. 2000. Characterization of binding of *Candida albicans* to small intestinal mucin and its role in adherence to mucosal epithelial cells. *Infect Immun.* 68(6):3172-9.
- Dehio, C., S.D. Gray-Owen and T.F. Meyer. 2000. Host cell invasion by pathogenic *Neisseriae*. *Subcell Biochem* 33:61-96.
- Deitsch, K.W., E.R. Moxon and T.E. Wellems. 1997. Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections. *Microbiol Mol Biol Rev.* 61:281-93
- Dinges, M.M., P.M. Orwin and P.M. Schlievert. 2000. Exotoxins of *Staphylococcus aureus*. *Clin Microbiol Rev.* 13(1):16-34
- Dobrindt, U., B. Hochhut, U. Hentschel and J. Hacker. 2004. Genomic islands in pathogenic and environmental microorganisms. *Nature Rev. Microbiol.* 2, 414-24
- Dodson, KW, J.S. Pinkner, T. Rose, G. Magnusson, S.J. Hultgren and G. Waksman. 2001. Structural basis of the interaction of the pyelonephritic *E. coli* adhesin to its human kidney receptor. *Cell* 105(6):733-743.
- Dombek, PE, Cue D, Sedgewick J, Lam H, Ruschkowski S, Finlay BB and Cleary PP. 1999. High-frequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements. *Mol Microbiol.* 31(3):859-70.
- Doran, KS, J.C. Chang, V.M. Benoit, L. Eckmann and V. Nizet. 2002. Group B streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. *J Infect Dis.* 185(2):196-203.
- Duclos, S. and M. Desjardins. 2000. Subversion of a young phagosome: the survival strategies of intracellular pathogens. *Cell. Microbiol.* 2:365-377.
- Duguid, J.P., I.W. Smith, G. Dempster and P.N. Edmunds. 1955. Non-flagellar filamentous appendages (fimbriae) and haemagglutinating activity in *Bacterium coli*. *J Pathol Bacteriol.* 70(2):335-48.
- Edwards, J.L., D.D. Entz and M.A. Apicella. 2003. Gonococcal phospholipase d modulates the expression and function of complement receptor 3 in primary cervical epithelial cells. *Infect Immun.* 71(11):6381-91.
- El Tahir, Y. and M. Skurnik. 2001. YadA, the multifaceted *Yersinia* adhesin. *Int J Med Microbiol.* 2001 Aug;291(3):209-18.
- Ekkelenkamp M.B., M. Hanssen, S.T. Danny Hsu, A. de Jong, D. Milatovic, J. Verhoef and N.A. van Nuland. 2005. Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of *Staphylococcus epidermidis*. *FEBS Lett.* 28;579(9):1917-22.
- Environment Canada. 2004. Guidance document for testing the pathogenicity and toxicity of new microbial substances to aquatic and terrestrial organisms. EPS 1/RM/44 March 2004

- Ernst, J.D. 2000. Bacterial inhibition of phagocytosis. *Cell Microbiol.* 2(5):379-86.
- Finlay, B.B. and Cossart P. 1997. Exploitation of mammalian host cell functions by bacterial pathogens. *Science*.276(5313):718-25. Erratum in: *Science* 278(5337):373.
- Falkow, S. 1988. Molecular Koch's postulates applied to microbial pathogenicity. *Rev Infect Dis.* 10:S274-6
- Falkow, S. 2008. Bacterial Pathogenicity in a Historical and Experimental Perspective. *Presentation at Microbial Evolution and co-Adaptation A Workshop in Honor of Joshua Lederberg.* 20 May, 2008. Institute of Medicine, Washington DC. (<http://www.iom.edu/CMS/3783/3924/52347/54694.aspx>)
- Field, D., D. Hood and R. Moxon. 1999. Contribution of genomics to bacterial pathogenesis. *Curr Opin Genet Dev.* 9:700-3
- Finlay, B.B. and S. Falkow. 1989. Common themes in microbial pathogenicity. *Microbiol Rev* 53:210-230
- Finlay, B.B. and S. Falkow. 1997. Common themes in microbial pathogenicity revisited. *Microbiol Mol Biol Rev.* 1997 Jun;61(2):136-69.
- Finn T.M., and D.F. Amsbaugh. 1998. Vag8, a *Bordetella pertussis* bvg-regulated protein. *Infect Immun.* 66(8):3985-9.
- Finn, T.M. and L.A. Stevens. 1995. Tracheal colonization factor: a *Bordetella pertussis* secreted virulence determinant. *Mol Microbiol.* 16(4):625-34.
- Foong, S.C. and J.S. Dickson. 2004. Attachment of *Listeria monocytogenes* on ready-to-eat meats. *J Food Prot.* 67(3):456-62.
- Fouet, A. and S. Mesnage. 2002. *Bacillus anthracis* cell envelope components. *Curr Top Microbiol Immunol.* 271:87-113.
- Fournier B. and D.J. Philpott. 2005. Recognition of *Staphylococcus aureus* by the innate immune system. *Clin Microbiol Rev.* 18(3):521-40.
- Franzon, V.L., A. Barker and P.A. Manning. 1993. Nucleotide sequence encoding the mannose-fucose-resistant hemagglutinin of *Vibrio cholerae* O1 and construction of a mutant. *Infect Immun.* 61(7):3032-7.
- Fredricks, D.N. and D.A. Relman. 1996. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. *Clin Microbiol Rev.* 9:18-33
- Frosch, M., Reidl, J. and Vogel, U. 1998. Genomics in infectious diseases: approaching the pathogens. *Trends Microbiol* 6:346-9
- Futagawa-Saito K. , T. Sugiyama, S. Karube, N. Sakurai, W. Ba-Thein, and T. Fukuyasu. 2004. Prevalence and characterization of leukotoxin-producing *Staphylococcus intermedius* in Isolates from dogs and pigeons. *J Clin Microbiol.* 42(11):5324-6.
- Gao, L.Y., F. Laval, E.H. Lawson, R.K. Groger, A. Woodruff, J.H. Morisaki, J.S. Cox, M. Daffe M and E.J. Brown. 2003. Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. *Mol Microbiol.* 49(6):1547-63.

- Garton N.J., M. Gilleron, T. Brando, H.H. Dan, S. Giguere, G. Puzo and J.F. Prescott, I.C. Sutcliffe. 2002. A novel lipoarabinomannan from the equine pathogen *Rhodococcus equi*. Structure and effect on macrophage cytokine production. *J Biol Chem.* 277(35):31722-33.
- Geuijen, C.A., R.J. Willems, M. Bongaerts, J. Top, H. Gielen and F.R. Mooi. 1997. Role of the *Bordetella pertussis* minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. *Infect. Immun.* 65:4222-4228.
- Ghigo, E., C. Christian, C-H. Tung, D. Raoult, J-P. Gorvel and J-L Mege. 2002. *Coxiella burnetti* survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN- γ mediates its restoration and bacterial killing. *J. Immunol.* 169:4488-4495.
- Gilbert, P., J. Das and I. Foley. 1997. Biofilm susceptibility to antimicrobials. *Adv Dent Res.* 1997 Apr;11(1):160-7.
- Gill, D.M. 1982. Bacterial Toxins: a Table of Lethal Amounts. *Microbiol. Rev.* 46:86-95.
- Gill, D.M. 1987. Bacterial Toxins: Descriptions. In: A.I. Laskin and H.A. Lechevalier (eds.). *CRC Handbook of Microbiology*, 2nd edition, Vol VIII, Toxins and Enzymes, 16 pp. CRC Press, Boca Raton, FL.
- Girish, K.S., R. Shashidharamurthy, S. Nagaraju, T.V. Gowda and K. Kemparaju. 2004. Isolation and characterization of hyaluronidase a "spreading factor" from Indian cobra (*Naja naja*) venom. *Biochimie.* 2004 Mar;86(3):193-202.
- Gladysheva, I.P., R.B. Turner, I.Y. Sazonova, L. Liu and G.L. Reed. 2003. Coevolutionary patterns in plasminogen activation. *Proc Natl Acad Sci U S A.* 100(16):9168-72.
- Glomski, I.J., M.M. Gedde, A.W. Tsang, J.A. Swanson and D.A. Portnoy DA. 2002. The *Listeria monocytogenes* hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. *J Cell Biol.* 156(6):1029-38.
- Goosney, D.L., R. DeVinney and B.B. Finlay. 2001. Recruitment of cytoskeletal and signalling proteins to enteropathogenic and enterohemorrhagic *Escherichia coli* pedestals. *Infect Immun* 69:3315-3322.
- Gouin, E., H. Gantelet, C. Egile, I. Lasa, H. Ohayon, V. Villiers, P. Gounon, P.J. Sansonetti and P. Cossart 1999. A comparative study of the actin-based motilities of the pathogenic bacteria *Listeria monocytogenes*, *Shigella flexneri* and *Rickettsia conorii*. *J Cell Sci.* 112 (Pt 11):1697-708.
- Gradon, J.D., J.G. Timpono and S.M. Schnittman. 1992. Emergence of unusual opportunistic pathogens in AIDS: a review. *Clin Infect Dis* 15:134-57
- Grange, P.A., M.A. Mouricout, S.B. Levery, D.H. Francis and A.K. Erickson. 2002. Evaluation of receptor binding specificity of *Escherichia coli* K88 (F4) fimbrial adhesin variants using porcine serum transferrin and glycosphingolipids as model receptors. *Infect Immun* 70:2336-2343.
- Guhathakurta B., D. Sasmal, A.N. Ghosh, R. Kumar, P. Saha, D. Biswas, D. Khetawat and A. Datta. 1999. Adhesion and invasion of a mutant *Shigella flexneri* to an eukaryotic cell line in absence of the 220-kb virulence plasmid. *FEMS Microbiol Lett.* 1999 Dec 15;181(2):267-75.
- Hackstadt, T. and J.C. Williams. 1981. Biochemical strategem for obligate parasitism of eukaryotic cells by *Coxiella burnetti*. *Proc. Natl. Acad. Sci.* 78:3240-3244.

- Harb, O.S. and Y.A. Kwaik. 1999. Probing the microenvironment of intracellular bacterial pathogens. *Microbes Infect.* 1: 445-53
- Hardy, G.G., S.M. Tudor and J.W. St.Geme III. 2003. The pathogenesis of disease due to nontypeable *Haemophilus influenzae*. *Methods Mol. Med.* 71:1-28.
- Hase, C.C. and J.J. Mekalanos. 1998. TcpP protein is a positive regulator of virulence gene expression in *Vibrio cholerae*. *Proc Natl Acad Sci U S A.* 95(2):730-4.
- Hauck, C.R. 2002. Cell adhesion receptors - signalling capacity and exploitation by bacterial pathogens. *Med Microbiol Immunol.* 191(2):55-62.
- Hauck, C.R. and T.F. Meyer. 2003. 'Small' talk: Opa proteins as mediators of *Neisseria*-host-cell communication. *Curr Opin Microbiol* 6:43-49
- Hayward, R.D., P.J. Hume, E.J. McGhie and V. Koronakis. 2002. A *Salmonella* SipB-derived polypeptide blocks the 'trigger' mechanism of bacterial entry into eukaryotic cells. *Mol Microbiol.* 2002 Sep;45(6):1715-27.
- Hazenbos, W.L., B.M. van den Berg, C.W. Geuijen, F.R. Mooi and R. van Furth. 1995. Binding of FimD on *Bordetella pertussis* to very late antigen-5 on monocytes activates complement receptor type 3 via protein tyrosine kinases. *J Immunol* 155:3972-3978.
- Hazenbos, W.L., B.M. van den Berg, J.W. van't Wout, F.R. Mooi and R. van Furth. 1994. Virulence factors determine attachment and ingestion of nonopsonized and opsonized *Bordetella pertussis* by human monocytes. *Infect Immun* 62:4818-4824.
- Heilmann C., G. Thumm, G.S. Chhatwal, J. Hartleib, A. Uekotter and G. Peters. 2003. Identification and characterization of a novel autolysin (Aae) with adhesive properties from *Staphylococcus epidermidis*. *Microbiology.* 149(Pt 10):2769-78.
- Henderson B., S. Poole and M. Wilson. 1996. Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. *Microbiol Rev.* 60(2):316-41.
- Henderson I.R., F. Navarro-Garcia and J.P. Nataro. 1998. The great escape: structure and function of the autotransporter proteins. *Trends Microbiol.* 6(9):370-8.
- Henderson, I.R. and P. Owen. 1999. The major phase-variable outer membrane protein of *Escherichia coli* structurally resembles the immunoglobulin A1 protease class of exported protein and is regulated by a novel mechanism involving Dam and oxyR. *J Bacteriol.* 181(7):2132-41.
- Hicks S, G. Frankel, J.B. Kaper, G. Dougan and A.D. Phillips. 1998. Role of intimin and bundle-forming pili in enteropathogenic *Escherichia coli* adhesion to pediatric intestinal tissue in vitro. *Infect Immun* 66:1570-1578.
- Hingley-Wilson S.M., V.K. Sambandamurthy, W.R. Jacobs Jr. 2003. Survival perspectives from the world's most successful pathogen, *Mycobacterium tuberculosis*. *Nat Immunol.* 4(10):949-55.
- Hooshangi, S. and W.E. Bentley. 2008. From unicellular properties to multicellular behavior: bacteria quorum sensing circuitry and applications. *Curr Opin Biotechnol* 19:550-555

- Hughey, V.L. and E.A. Johnson. 1987. Antimicrobial activity of lysozyme against bacteria involved in food spoilage and food-borne disease. *Appl Environ Microbiol.* 53(9):2165-70.
- Hultgren, S.J., S. Abraham, M. Caparon, P. Falk, J.W. St. gene III and S. Normark. 1993. Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition. *Cell.* 73(5):887-901.
- Hynes, W.L., A.R. Dixon, S.L. Walton and L.J. Aridgides. 2000. The extracellular hyaluronidase gene (*hlyA*) of *Streptococcus pyogenes*. *FEMS Microbiol Lett.* 184(1):109-12.
- Ilver, D., A. Arnqvist, J. Ogren, I.M. Frick, D. Kersulyte, E.T. Incecik, D.E. Berg, A. Covacci, L. Engstrand and T. Boren. 1998. *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science.* 279(5349):373-7.
- Imberty, A., M. Wimmerova, E.P. Mitchell and N. Gilboa-Garber. 2004. Structures of the lectins from *Pseudomonas aeruginosa*: insight into the molecular basis for host glycan recognition. *Microbes Infect.* 6:221-8.
- Isberg, R.R. and P. Barnes. 2001. Subversion of integrins by enteropathogenic *Yersinia*. *J Cell Science* 114:21-28.
- Isberg, R.R. and J.M. Leong. 1988. Cultured mammalian cells attach to the invasin protein of *Yersinia pseudotuberculosis*. *Proc Natl Acad Sci U S A.* 85(18):6682-6.
- Isberg, R.R. and J.M. Leong. 1990. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. *Cell.* 60(5):861-71.
- Ishibashim, Y., K. Yoshimura, A. Nishikawa, S. Claus, C. Laudanna and D.A. Relman. 2002. Role of phosphatidylinositol 3-kinase in the binding of *Bordetella pertussis* to human monocytes. *Cell Microbiol* 4:825-833.
- Ishikawa, K., B. Sundelin, R. Mollby, S. Normark and J. Winberg. 2004. Receptors for *Escherichia coli* adhesins in the genitourinary tract in a non-human primate. *Scand J Urol Nephrol.* 38(1):3-14.
- Jett, B.D., M.M. Huycke, and M.S. Gilmore. 1994. Virulence of enterococci. *Clin Microbiol Rev.* 7(4):462-78.
- Johnson, J.R. 1991. Virulence factors in *Escherichia coli* urinary tract infection. *Clin Microbiol Rev.* 4(1):80-128.
- Johnson, J.R., A.L. Stell, N. Kaster, C. Fasching and T.T. O'Bryan. 2001. Novel molecular variants of allele I of the *Escherichia coli* P fimbrial adhesin gene *papG*. *Infect Immun* 69:2318-2327.
- Kachlany, S.C., P.J. Planet, M.K. Bhattacharjee, E. Kollia, R. DeSalle, D.H. Fine and D.H. Figurski. 2000. Nonspecific adherence by *Actinobacillus actinomycetemcomitans* requires genes widespread in bacteria and archaea. *J Bacteriol.* 182(21):6169-76.
- Kathariou, S.A. 2002. *Listeria monocytogenes* virulence and pathogenicity, a food safety perspective. *J Food Prot* 65:1811-1829.
- Kerr, J.R. 1999. Cell adhesion molecules in the pathogenesis of and host defense against microbial infection. *J. Clin Pathol:Mol Pathol* 52:220-230

- Kingsley, R.A., A.M. Kestra, M.R. de Zoete, A.J. Baumler. 2004. The ShdA adhesin binds to the cationic cradle of the fibronectin 13FnIII repeat module: evidence for molecular mimicry of heparin binding. *Mol Microbiol.* 52(2):345-55.
- Kingsley, R.A., R.L. Santos, A.M. Kestra, L.G. Adams and A.J. Baumler. 2002. *Salmonella enterica* serotype Typhimurium ShdA is an outer membrane fibronectin-binding protein that is expressed in the intestine. *Mol Microbiol.* 43(4):895-905.
- Kjaergaard, K., M.A. Schembri, H. Hasman, and P. Klemm. 2000. Antigen 43 from *Escherichia coli* induces inter- and intraspecies cell aggregation and changes in colony morphology of *Pseudomonas fluorescens*. *J Bacteriol.* 182(17):4789-96.
- Klein, M.B., S. Hu, C.C. Chao and J.L. Goodman. 2000. The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. *J. Infect. Dis.* 182: 200-205.
- Klemm, P. and M.A. Schembri. 2000. Bacterial adhesins: function and structure. *Int J Med Microbiol* 290:27-35.
- Klose, K.E. and J.J. Mekalanos. 1997. Simultaneous prevention of glutamine synthesis and high-affinity transport attenuates *Salmonella typhimurium* virulence. *Infect Immun.* 65:587-96
- Kohler, H., S.P. Rodrigues and B.A. McCormick. 2002. *Shigella flexneri* Interactions with the Basolateral Membrane Domain of Polarized Model Intestinal Epithelium: Role of Lipopolysaccharide in Cell Invasion and in Activation of the Mitogen-Activated Protein Kinase ERK. *Infect Immun.* 70(3):1150-8.
- Kong, K-F., C. Vuong and M. Otto. 2006. *Staphylococcus* quorum sensing in biofilm formation and infection. *Int J. Med Microbiol* 296:
- Kreikemeyer, B., S. Oehmcke, M. Nakata, R. Hoffrogge and A. Podbielski. 2004. *Streptococcus pyogenes* fibronectin-binding protein F2: expression profile, binding characteristics, and impact on eukaryotic cell interactions. *J Biol Chem.* 279(16):15850-9.
- Kuehn M.J., and N.C. Kesty. 2005. Bacterial outer membrane vesicles and the host-pathogen interaction. *Genes Dev.* 19(22):2645-55.
- Kuhn-Nentwig, L., J. Schaller and W. Nentwig. 2004. Biochemistry, toxicology and ecology of the venom of the spider *Cupiennius salei* (Ctenidae). *Toxicon.* 2004 Apr;43(5):543-53.
- Kwok, T., S. Backert, H. Schwarz, J. Berger and T.F. Meyer. 2002. Specific entry of *Helicobacter pylori* into cultured gastric epithelial cells via a zipper-like mechanism. *Infect Immun.* 70(4):2108-20.
- Laarmann, S., D. Cutter, T. Juehne, S.J. Barenkamp and J.W. St. Geme III. 2002. The *Haemophilus influenzae* Hia autotransporter harbours two adhesive pockets that reside in the passenger domain and recognize the same host cell receptor. *Mol Microbiol* 46:731-743.
- Lafontaine, E.R., L.D. Cope, C. Aebi, J.L. Latimer, G.H. McCracken Jr. and E.J. Hansen. 2000. The UspA1 protein and a second type of UspA2 protein mediate adherence of *Moraxella catarrhalis* to human epithelial cells in vitro. *J Bacteriol.* 2000 Mar;182(5):1364-73.

- Lally, E.T., R.B. Hill, I.R. Kieba and J. Korostoff. 1999. The interaction between RTX toxins and target cells. *Trends Microbiol.* 7(9):356-61.
- Lecuit, M., H. Ohayon, L. Braun, J. Mengaud and P. Cossart. 1997. Internalin of *Listeria monocytogenes* with an intact leucine-rich repeat region is sufficient to promote internalization. *Infect Immun.* 65(12):5309-19.
- Lee, J.H., H.J. Choi, J. Jung, M.G. Lee, J.B. Lee and K.H. Lee. 2003. Receptors for *Treponema pallidum* attachment to the surface and matrix proteins of cultured human dermal microvascular endothelial cells. *Yonsei Med J.* 44(3):371-8.
- Lee, S.Y. and R.E. Klevit. 2000. The whole is not the simple sum of its parts in calmodulin from *S. cerevisiae*. *Biochemistry* 39, 4225-30
- Legat, F.J., T. Griesbacher and F. Lembeck. 1994. Mediation by bradykinin of rat paw oedema induced by collagenase from *Clostridium histolyticum*. *Br J Pharmacol.* 112(2):453-60.
- Li, J., N.F. Fairweather, P. Novotny, G. Dougan and I.G. Charles. 1992. Cloning, nucleotide sequence and heterologous expression of the protective outer-membrane protein P.68 pertactin from *Bordetella bronchiseptica*. *J Gen Microbiol.* 138 (Pt 8):1697-705.
- Li, S., S.J. Kelly, E. Lamani, M. Ferraroni and M.J. Jedrzejak. 2000. Structural basis of hyaluronan degradation by *Streptococcus pneumoniae* hyaluronate lyase. *EMBO J.* 19(6):1228-40.
- Lindenthal, C. and E.A. Elsinghorst. 1999. Identification of a glycoprotein produced by enterotoxigenic *Escherichia coli*. *Infect Immun.* 67(8):4084-91.
- Liu, H., P. Radhakrishnan, L. Magoun, M. Prabu, K.G. Campellone, P. Savage, F. He, C.A. Schiffer and J.M. Leong. 2002. Point mutants of EHEC intimin that diminish Tir recognition and actin pedestal formation highlight a putative Tir binding pocket. *Mol Microbiol* 45:1557-1573.
- Lyon, G.J., J.S. Wright, A. Christopoulos, R.P. Novick and T.M. Mui. 2002. Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. *J Biol Chem* 277: 6247-6253
- Mahenthiralingham, E, T.A. Urban and J.B. Goldberg. 2005. The multifarious, multireplicon *Burkholderia cepacia* complex. *Nature Rev Microbiol* 3:144-156
- Mahan, M.J., J.M. Slauch and J.J. Mekalanos. 1993. Selection of bacterial virulence genes that are specifically induced in host tissues. *Science* 259:686-8
- Marques, M.A.M., V.L. Antônio, E.N. Sarno, P.J. Brennan and M.C.V. Pessolani. 2001. Binding of α -laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. *J Med Microbiol* 50:23-28.
- Martinez de Tejada, G., J. Pizarro-Cerda, I. Moreno E and I. Moriyon. 1995. The outer membranes of *Brucella* spp. are resistant to bactericidal cationic peptides. *Infect Immun.* 63(8):3054-61.
- Mattoo, S., A.K. Foreman-Wykert, R.A. Cotter and J. Miller. 2001. Mechanisms of *Bordetella* pathogenesis. *Front Biosci* 6:168-186

- Maurelli, A. T., R.E. Fernandez, C.A. Bloch, C.k. Rode and A. Fasano. 1998. 'Black holes' and bacterial pathogenicity: a large genomic deletion that enhances the virulence of *Shigella* spp. and enteroinvasive *Escherichia coli*. Proc. Natl Acad. Sci. USA 95, 3943–3948
- McCaw, S.E., E.H. Liao and S.D. Gray-Owen. 2004. Engulfment of *Neisseria gonorrhoeae*: revealing distinct processes of bacterial entry by individual carcinoembryonic antigen-related cellular adhesion molecule family receptors. Infect Immun. 72(5):2742-52.
- McCrea, K.W., W.J. Waston, J.R. Gilsdorf and C.F. Marrs. 1997. Identification of two minor subunits in the pilus of *Haemophilus influenzae*. J Bacteriol 179:4227-4231.
- McGuirk, P., C. McCann and K. H.G. Mills. 2002. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by *Bordetella pertussis*. J Exp Med 195:221-231.
- Menzies, B.E. and I. Kourteva. 2000. *Staphylococcus aureus* alpha-toxin induces apoptosis in endothelial cells. FEMS Immunol Med Microbiol. 2000 Sep;29(1):39-45.
- Merrell, D.S., L.J. Thompson, C.C. Kim, H. Mitchell, L.S. Tompkins, A. Lee and S. Falkow. 2003. Growth phase-dependent response of *Helicobacter pylori* to iron starvation. Infect Immun. 71(11):6510-25.
- Merz, A.J. and M. So. 2000. Interactions of pathogenic *Neisseriae* with epithelial cell membranes. Annu Rev Cell Dev Biol 16:423-457.
- Meyer, D.H., K.P. Mintz and P.M. Fives-Taylor. 1997. Models of invasion of enteric and periodontal pathogens into epithelial cells: a comparative analysis. Crit Rev Oral Biol Med. 1997;8(4):389-409.
- Middleton, A.M., M.V. Chadwick, A.G. Nicholson, A. Dewar, R.K. Groger, E.J. Brown and R. Wilson. 2000. The role of *Mycobacterium avium* complex fibronectin attachment protein in adherence to the human respiratory mucosa. Mol Microbiol 38:381-391.
- Mims, C., A. Nash and J. Stephen (eds.) 2001. Attachment to and entry of microorganisms into the body. In: Mims' Pathogenesis of Infectious Disease. Academic Press, San Diego.
- Molinari, G. and G.S. Chhatwal. 1999. Streptococcal invasion. Curr Opin Microbiol. 2(1):56-61.
- Molinari, G., M. Rohde, C.A. Guzman and G.S. Chhatwal. 2000. Two distinct pathways for the invasion of *Streptococcus pyogenes* in non-phagocytic cells. Cell Microbiol. 2(2):145-54.
- Molinari, G., S.R. Talay, P. Valentin-Weigand, M. Rohde and G.S. Chhatwal. 1997. The fibronectin-binding protein of *Streptococcus pyogenes*, SfbI, is involved in the internalization of group A streptococci by epithelial cells. Infect Immun. 65(4):1357-63.
- Moncada, D., Y. Yu, K. Keller and K. Chadee. 2000. *Entamoeba histolytica* cysteine proteinases degrade human colonic mucin and alter its function. Arch Med Res. 31(4 Suppl):S224-5.
- Morinaga, N., Y. Kaihou and M. Noda. 2003. Purification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol Immunol. 47(1):81-90.

- Mueller-Ortiz, S.L., A.R. Wanger and S.J. Norris. 2001. Mycobacterial protein HbhA binds human complement component C3. *Infect Immun* 69:7501-7511.
- Nagy, B. and P.Z. Fekete. 1999. Enterotoxigenic *Escherichia coli* (ETEC) in farm animals. *Vet Res* 30:259-284.
- Narayanan, S.K., T.G. Nagaraja, M.M. Chengappa and G.C. Stewart. 2002. Leukotoxins of gram-negative bacteria. *Vet Microbiol.* 84(4):337-56.
- Nizet, V. 2002. Streptococcal beta-hemolysins: genetics and role in disease pathogenesis. *Trends Microbiol.* 10(12):575-80.
- Nougayrède, J-P., S. Homburg, F. Taieb, M. le Boury, E. Brzuszkiewicz, G. Gottschalk, C. Buchrieser, J. Hacker, U. Dobrindt, E. Oswald. 2006. *Escherichia coli* Induces DNA Double-Strand Breaks in Eukaryotic Cells. *Science* 848: 313.
- OECD 1986. Recombinant DNA safety considerations. OECD Paris
- O'Neill, J.M., J.W. St. Geme III, D. Cutter, E.E. Adderson, J. Anyanwu, R.F. Jacobs and G.E. Schutze. 2003. Invasive disease due to nontypeable *Haemophilus influenzae* among children in Arkansas. *J Clin Microbiol* 41:3064-3069.
- Parkkinen, J., T.K. Korhonen, A. Pere, J. Hacker and S. Soinila. 1988. Binding sites in the rat brain for *Escherichia coli* S fimbriae associated with neonatal meningitis. *J Clin Invest.* 81(3):860-5.
- Paton, J.C., P.W. Andrew, G.J. Boulnois and T.J. Mitchell. 1993. Molecular analysis of the pathogenicity of *Streptococcus pneumoniae*: the role of pneumococcal proteins. *Annu Rev Microbiol.* 1993;47:89-115.
- Paton, J.C. and A. Ferrante. 1983. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. *Infect Immun.* 41(3):1212-6.
- Poilane, I., T. Karjalainen, M.C. Barc, P. Bourlioux and A. Collignon. 1998. Protease activity of *Clostridium difficile* strains. *Can J Microbiol.* 44(2):157-61.
- Ponnuraj, K., M.G. Bowden, S. Davis, S. Gurusiddappa, D. Moore, D. Choe, Y. Xu, M. Hook and S.V. Narayana. 2003. A "dock, lock, and latch" structural model for a staphylococcal adhesin binding to fibrinogen. *Cell.* 2003 Oct 17;115(2):217-28.
- Porte, F., J.P. Liautard and S. Kohler. 1999. Early acidification of phagosomes containing *Brucella suis* is essential for intracellular survival in murine macrophages. *Infect Immun.* 67(8):4041-7.
- Quinn, F.D., G.W. Newman and C.H. King. 1997. In search of virulence factors of human bacterial disease. *Trends Microbiol.* 5: 20-6
- Rajkumar, R., H. Devaraj and S. Niranjali. 1998. Binding of *Shigella* to rat and human intestinal mucin. *Mol Cell Biochem.* 178(1-2):261-8.
- Rathman, R., M.D. Sjaastad and S. Falkow. 1996. Acidification of phagosomes containing *Salmonella typhimurium* in murine macrophages. *Infect. Immun.* 64:2765-2773.

- Ramachandra, L, E. Noss, W.H. Boom and V.V. Harding. 1999. Phagocytic processing of antigens for presentation by class II major histocompatibility complex molecules. *Cell Microbiol.* 1(3):205-14.
- Relman, D.A., M. Domenighin, E. Tuomanen, R. Rappuoli and S. Falkow. 1989. Filamentous hemagglutinin of *Bordetella pertussis*: nucleotide sequence and crucial role in adherence. *Proc Natl Acad Sci U S A.* 86:2637-2641.
- Ringdahl, U., M. Svensson, A.C. Wistedt, T. Renne, R. Kellner, W. Muller-Esterl and U. Sjobring. 1998. Molecular co-operation between protein PAM and streptokinase for plasmin acquisition by *Streptococcus pyogenes*. *J Biol Chem.* 1998 Mar 13;273(11):6424-30.
- Roche, F.M., R. Downer, F. Keane, P. Speziale, P.P. Woo and T.J. Foster. 2004. The amino-terminal A domain of fibronectin binding proteins A and B promotes adhesion of *Staphylococcus aureus* to elastin. *J Biol Chem.* Jul 6 Epub 2004 Jul 02.
- Rogolsky, M. 1979. Nonenteric toxins of *Staphylococcus aureus*. *Microbiol Rev.* 43(3):320-60.
- Rood, J.I. 1998. Virulence genes of *Clostridium perfringens*. *Annu Rev Microbiol.* 1998;52:333-60.
- Ryan, P.A., V. Pancholi and V.A. Fischetti. 2001. Group A streptococci bind to mucin and human pharyngeal cells through sialic acid-containing receptors. *Infect Immun.* 69(12):7402-12
- Sajjan, U.S., L. Sun, R. Goldstein and J.F. Forstner. 1995. Cable (cbl) type II pili of cystic fibrosis-associated *Burkholderia (Pseudomonas) cepacia*: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers. *J Bacteriol.* 177(4):1030-8.
- Salyers, A.A. and D.D. Whitt (eds). 2002. Bacterial pathogenesis, a molecular approach, 2nd edition, p. 118-119. ASM Press, Washington D.C.
- Samrakandi, M.M., D. A. Ridenour, L. Yan and J.D. Cirillo. 2002. Entry into host cells by *Legionella*. *Front Biosci* 7:d1-11.
- Saren, A, R. Virkola, J. Hacker and T.K. Korhonen. 1999. The cellular form of human fibronectin as an adhesion target for the S fimbriae of meningitis-associated *Escherichia coli*. *Infect Immun* 67(5):2671-2676.
- Sasmal, D., B. Guhathakurta, S.K. Bhattacharya, C.R. Pal, A. Datta. 2002. N-acetyl-D-glucosamine specific hemagglutinin receptor of *Vibrio cholerae* O1 in chicken erythrocyte membranes. *FEMS Immunol Med Microbiol.* 32(3):187-9.
- Schmidt, H. and M. Hensel. 2004. Pathogenicity islands in bacterial pathogenesis. *Clin Microbiol Reviews* 17:14-56
- Schorey, J.S., M.A. Holsti, T.L. Ratliff, P.M. Allen and Eric, J. Brown. 1996. Characterization of the fibronectin-attachment protein of *Mycobacterium avium* reveals a fibronectin-binding motif conserved among mycobacteria. *Mol Microbiol* 21:321-329.
- Schulte, R., S. Kerneis, S. Klinke, H. Bartels, S. Preger, J.P. Kraehenbuhl, E. Prinault and I.B. Autenrieth. 2000. Translocation of *Yersinia enterocolitica* across reconstituted intestinal epithelial monolayers is triggered by *Yersinia* invasin binding to β_1 integrins apically expressed on M-like cells. *Cell Microbiol* 2:173-185.

- Schwan, W.R., J.L. Lee, F.A. Lenard, B.T. Matthews and M.T. Beck. 2002. Osmolarity and pH growth conditions regulate fim gene transcription and type 1 pilus expression in uropathogenic *Escherichia coli*. *Infect Immun.* 70(3):1391-402.
- Shabtai, Y. and G. Fleminger. 1994. Adsorption of *Rhodococcus* Strain GIN-1 (NCIMB 40340) on Titanium Dioxide and Coal Fly Ash Particles. *Appl Environ Microbiol.* 60(9):3079-3088.
- Sierig, G., C. Cywes, M.R. Wessels and C.D. Ashbaugh. 2003. Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. *Infect Immun.* 71(1):446-55.
- Seto, S. and M. Miyata. 2003. Attachment organelle formation represented by localization of cytoadherence proteins and formation of the electron-dense core in wild-type and mutant strains of *Mycoplasma pneumoniae*. *J Bact* 185:1082-1091.
- Shuter, J., V.B. Hatcher and F.D. Lowy. 1996. *Staphylococcus aureus* binding to human nasal mucin. *Infect Immun.* 64(1):310-8.
- Smith, R.L. and M.E. Maguire. 1998. Microbial magnesium transport: unusual transporters searching for identity. *Mol Microbiol.* 28:217-26
- Soto, G.E. and S.J. Hultgren. 1999. Bacterial adhesins: common themes and variations in architecture and assembly. *J Bacteriol* 181:1059-1071.
- St. Geme III, J.W. 2002. Molecular and cellular determinants of non-typeable *Haemophilus influenzae* adherence and invasion. *Cell Microbiol* 4:191-200.
- St. Geme III, J.W., D. Cutter and S.J. Barenkamp. 1996. Characterization of the genetic locus encoding *Haemophilus influenzae* type b surface fibrils. *J Bacteriol.* 178(21):6281-7.
- St. Geme III, J.W., M.L. de la Morena and S. Falkow. 1994. A *Haemophilus influenzae* IgA protease-like protein promotes intimate interaction with human epithelial cells. *Mol Microbiol.* 14(2):217-33.
- Stewart-Tull, D.E., C. Lucas and C.R. Bleakley. 2004. Experimental immunisation and protection of guinea pigs with *Vibrio cholerae* toxoid and mucinases, neuraminidase and proteinase. *Vaccine.* 22(17-18):2137-45.
- Stratton, H.M., P.R. Brooks, P.C. Griffiths and R.J. Seviour. 2002. Cell surface hydrophobicity and mycolic acid composition of *Rhodococcus* strains isolated from activated sludge foam. *J Ind Microbiol Biotechnol* 28:264-267.
- Strauss, E.J. and S. Falkow. 1997. Microbial pathogenesis: genomics and beyond. *Science* 276:707-11
- Strauss, E.J., N. Ghori and S. Falkow. 1997. An *Edwardsiella tarda* strain containing a mutation in a gene with homology to shlB and hpmB is defective for entry into epithelial cells in culture. *Infect Immun.* 65(9):3924-32.
- Strom, M.S. and S. Lory. 1993. Structure-function and biogenesis of the type IV pili. *Annu Rev Microbiol.* 47:565-96.

- Thankavel, K., A.H. Shah, M.S. Cohen, T. Ikeda, R.G. Lorenz, R. Curtiss 3rd and S.N. Abraham. 1999. Molecular basis for the enterocyte tropism exhibited by *Salmonella typhimurium* type 1 fimbriae. *J Biol Chem.* 274(9):5797-809.
- Tobe, T. and C. Sasakawa. 2002. Species-specific cell adhesion of enteropathogenic *Escherichia coli* is mediated by type IV bundle-forming pili. *Cell Microbiol* 4:29-42.
- Touze, T., R.D. Hayward, J. Eswaran, J.M. Leong and V. Koronakis. 2004. Self-association of EPEC intimin mediated by the beta-barrel-containing anchor domain: a role in clustering of the Tir receptor. *Mol Microbiol.* 51(1):73-87.
- Towers, R.J., P.K. Fagan, S.R. Talay, B.J. Currie, K.S. Sriprakash, M.J. Walker and G.S. Chhatwal. 2003. Evolution of *sfhI* encoding streptococcal fibronectin-binding protein I: horizontal genetic transfer and gene mosaic structure. *J Clin Microbiol.* 41(12):5398-406.
- Toyooka, K., S. Takai and T. Kirikae. 2005. *Rhodococcus equi* can survive a phagolysosomal environment in macrophages by suppressing acidification of the phagolysosome. *J Med Microbiol.* 54(Pt 11):1007-15.
- Tsukano, H., F. Kura, S. Inoue, S. Sato, H. Izumiya, T. Yasuda and H. Watanabe. 1999. *Yersinia pseudotuberculosis* blocks the phagosomal acidification of B10.A mouse macrophages through the inhibition of vacuolar H(+)-ATPase activity. *Microb Pathog.* 27(4):253-63.
- Tullus, K. A., Brauner, B. Fryklund, T. Munkhammar, W. Rabsch, R. Reissbrodt and L.G. Burman. 1992. Host factors versus virulence-associated bacterial characteristics in neonatal and infantile bacteraemia and meningitis caused by *Escherichia coli*. *J Med Microbiol* 36:203-208.
- Tuomanen, E. and A. Weiss. 1985. Characterization of two adhesins of *Bordetella pertussis* for human ciliated respiratory-epithelial cells. *J Infect Dis* 152:118-125.
- Ukuku, D.O. and W.F. Fett. 2002. Relationship of cell surface charge and hydrophobicity to strength of attachment of bacteria to cantaloupe rind. *J Food Prot.* 65(7):1093-9.
- Urisu A., J.L. Cowell and C.R. Manclark. 1986. Filamentous hemagglutinin has a major role in mediating adherence of *Bordetella pertussis* to human WiDr cells. *Infect Immun* 52:695-701.
- Uzzau, S., G. Marogna, G.S. Leori, R. Curtiss III, G. Schianchi, B.A.D. Stocker and S. Rubino. 2005. *Infect Immun.* 73:4302-8
- Van den Berg, B.M., H. Beekhuizen, R.J. Willems, F.R. Mooi and R. van Furth. 1999. Role of *Bordetella pertussis* virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. *Infect Immun.* 67:1056-1062.
- Van den Broeck, W., E. Cox, B. Oudega and B.M. Goddeeris. 2000. The F4 fimbrial antigen of *Escherichia coli* and its receptors. *Vet Microbiol.* 71(3-4):223-44.
- Van der Goot, F.G., G. Tran Van Nhieu, A. Allaoui, P. Sansonetti P and F. Lafont. 2004. Rafts can trigger contact-mediated secretion of bacterial effectors via a lipid-based mechanism. *J Biol Chem.* 279, 47792-98
- Vasil, M.L. 1986. *Pseudomonas aeruginosa*: biology, mechanisms of virulence, epidemiology. *J Pediatr.* 108(5 Pt 2):800-5.

- Veiga, E., V. de Lorenzo and L.A. Fernandez. 2003. Autotransporters as scaffolds for novel bacterial adhesins: surface properties of *Escherichia coli* cells displaying Jun/Fos dimerization domains. *J Bacteriol.* 185(18):5585-90.
- Vuong C. and M. Otto. 2002. *Staphylococcus epidermidis* infections. *Microbes Infect.* 4(4):481-9.
- Ward, A.C., G.C. Weiser, W.J. DeLong and G.H. Frank. 2002. Characterization of *Pasteurella* spp isolated from healthy domestic pack goats and evaluation of the effects of a commercial *Pasteurella* vaccine. *Am J Vet Res.* 63(1):119-23.
- WHO. 2004. Laboratory biosafety manual. World Health Organization. Geneva
- Wassenaar, T.M. and W. Gaastra. 2001. Bacterial virulence: can we draw the line. *FEMS Microbiol Letters* 201:1-7 (see also http://www.cogem.net/ContentFiles/Rapport_bacterial_virulence.pdf)
- Waters, C.M. and B.L. Bassler B.L. 2005. Quorum sensing: cell-to-cell communication in bacteria. *Annu Rev Cell Dev Biol* 21:319-346.
- Wiggins, R, S.J. Hicks, P.W. Soothill, M.R. Millar and Corfield AP. 2001. Mucinases and sialidases: their role in the pathogenesis of sexually transmitted infections in the female genital tract. *Sex Transm Infect.* 77(6):402-8. Review.
- Wilson, R., R. Read, M. Thomas, A. Rutman, K. Harrison, V. Lund, B. Cookson, W. Goldman, H. Lambert and P. Cole. 1991. Effects of *Bordetella pertussis* infection on human respiratory epithelium in vivo and in vitro. *Infect Immun* 59:337-345.
- Wilson, J.W., M.J. Schurr, C.L. LeBlanc, R. Ramamurthy, K.L. Buchanan and C.A. Nickerson. 2002. Mechanisms of bacterial pathogenicity. *Postgrad Med J.* 78(918):216-24.
- Winther-Larsen, H.C., F.T. Hegge, M. Wolfgang, S.F. Hayes, J.P. van Putten and M. Koomey. 2001. *Neisseria gonorrhoeae* PilV, a type IV pilus-associated protein essential to human epithelial cell adherence *Proc Natl Acad Sci U S A.* 98(26):15276-81.
- Winzer, K, C. Falconer, N.C. Garber, S.P. Diggle, M. Camara and P. Williams. 2000. The *Pseudomonas aeruginosa* lectins PA-IL and PA-III are controlled by quorum sensing and by RpoS. *J Bacteriol.* 182(22):6401-11.
- Wolfgang, M., J.P. van Putten, S.F. Hayes, D. Dorward and M. Koomey. 2000. Components and dynamics of fiber formation define a ubiquitous biogenesis pathway for bacterial pili. *EMBO J.* 19(23):6408-18.
- Woolard, M.D. and J.A. Frelinger. 2008. Outsmarting the host: bacteria modulating the immune response. *Immunol Res* 41:188-202
- Yeo, H.J., S.E. Cotter, S. Laarmann, T. Juehne, J.W. St. geme III and G. Waksma. 2004. Structural basis for host recognition by the *Haemophilus influenzae* Hia autotransporter. *EMBO J.* 23(6):1245-56.
- Yoshiie, K., H.Y. Kim, J. Mott and Y. Rikihisa. 2000. Intracellular infection by the human granulocytic ehrlichiosis agent inhibits human neutrophil apoptosis. *Infect. Immun.* 68:1125-1133.
- Zecchinon, L., T. T. Fett and D. Desmecht. 2005. How *Mannheimia haemolytica* defeats host defense through a kiss of death mechanism. *Vet Res.* 36(2):133-56.